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GLOSSARY 
 
β2-m, Light Chain β2-microglobulin  
Ab, Antibody 
ABC, Ammonium Bicarbonate  
Ag, Antigen 
APC, Antigen Presenting Cells  
Arg, Arginine 
BCA, Bicinchoninic Acid Assay  
BHK, Baby Hamster Kidney  
BM-DCs, Bone Marrow-Dendritic Cells 
BSA, Bovine Serum Albumin  
CAN, Acetonitrile 
CD80, Cluster of differentiation 80 
CD86, Cluster of differentiation 86 
CE, Collision Energie 
CTL, Cytotoxic T Lymphocyte  
Da, Dalton 
DC, Dendritic Cell 
DDA, Data Dependent Acquisition  
DLinDMA, 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane  
DMP, Dimethyl pimelimidate  
DMEM, Dulbecco's Modified Eagle's Medium 
DOC, Sodium Deoxycholate  
DSPC, 1,2-Diasteroyl-sn-glycero-3-phosphocholine 
dsRNA, double strand RNA 
DTT, Dithiothreitol  
ELISA, Enzyme Linked Immunosorbent Assay 
ER, Endoplasmic Reticulum  
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EU/ml, ELISA Units per ml  
FA, Formic Acid 
FASP, Filter Assisted Sample Preparation 
FBS, Fetal Bovine Serum 
FITC, Fluorescent Isothiocyanate 
GOI, Gene of Interest  
H, Hour 
HCD, Higher energy Collision induced Dissociation  
HCV, Hepatitis C Virus 
HIV, Human Immunodeficiency Virus 
HLA, Human Leucocyte Antigen 
Hpi, Hours post infection 
HRP Ab, Horseradish Peroxidase conjugated Antibody 
IAA, Iodoacetamide  
ICS, Intracellular Staining  
IFNs, Interferons 
IgG, Immunoglobulin G  
Ile, Isoleucine 
I.m., Intra muscular  
IS, Internal Standard 
IS-PRM, Internal Standard-Parallel Reaction Monitoring  
IU, Infection Unit 
K, Lysine 
KHL, Keyhole Limpet Hemocyanin 
LC, Liquid Chromatography 
LiCl, Lithium Chloride 
LLOQ, Low Limit Of Quantification 
LNP, Lipid Nano Particle  
Lys, Lysine 
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mAb, Monoclonal Antibody 
MHC, Major Histocompatibility Complex system 
MHC I, Major Histocompatibility Complex Class I molecule 
MHC II, Major Histocompatibility Complex Class II molecule 
MRM, Multiple Reaction Monitoring 
mRNA, Messenger RNA 
MS, Mass Spectrometry 
NK, Natural Killer  
NP, Nucleoprotein  
Ns P (1-4), Nonstructural Protein (1-4) 
OD, Optical Density 
ORF, Open Reading Frame  
PBS, Phosphate Buffer Saline 
PDI, Protein Disulfide Isomerase  
p-DNA, Plasmid-DNA 
Pen/Strep/Glu, Penicillin/Strepmicyn/Glutamine  
PRM, Parallel Reaction Monitoring 
PS, Packaging Signal  
PTPs, Proteotypic Peptides 
PYG, Glycogen Phosphorylase  
PVDF Membrane, Polyvinylidene Difluoride Membrane 
Q1, First quadrupole 
Q2, Second quadrupole 
Q3, Third quadrupole  
q-TOF, Quadrupole-Time Of Flight mass spectrometer 
q-OT, Quadrupole-Orbitrap mass spectrometer 
QQQ, Triple Quadrupole  
R, Arginine  
RDRP, RNA-dependent RNA polymerase 
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RT, Room Temperature 
SAM, Self-amplifying mRNA vaccine 
SEAP, Secrete Alkaline Phosphatase  
SID, Stable Isotope Dilution method  
SISCAPA, Stable Isotope Standards and Capture by Anti-Peptide Antibodies  
SMCC, Succinimidyl trans-4-(Maleimidylmethyl)Cyclohexane-1-Carboxylate  
SRM, Selected Reaction Monitoring 
SV, Sindbis Virus  
TH, T helper  
TC, T cytotoxic 
TBS, Tris Buffer Saline  
TBST, Tris Buffer Saline plus Tween 20  
TAP, Transporter Associated with antigen Processing  
TCA, 2,2,2-trichloroacetic acid  
TCR, T Cell Receptor  
TIC, Total Ion Current  
UA, Urea 
UTR, Untranslated Region 
VCR, Chimeric Replicon Vector 
VEEV, Venezuelan Equine Encephalitis Virus 
VRP, Viral Replicon Particle 
V/V, Volume/Volume 
W/V, Weight/Volume 
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SUMMARY 
 
Nucleic acid-based vaccines such as viral vectors, plasmid DNA and mRNA have been 
developed as a means to address limitations of both live attenuated and subunit vaccines. Among 
them, Self Amplifying mRNA vaccine (SAM) has been widely evaluated in different animal 
models and has been confirmed to be well tolerated and able to drive in vitro antigen expression. 
However, the molecular mechanism of action of SAM approach has not been fully elucidated. To 
address this gap, we employed a quantitative mass spectrometry (MS) approach to investigate the 
molecular fate of vaccine antigens encoded by SAM, from RNA delivery, until MHC-peptide 
presentation.  
In this work, we investigated the quantitative correlation between the antigen expression and 
epitope presentation on MHC class I molecules in a dose-range and time-lapse assay using 
myoblast cell cultures. Two delivery systems were compared, viral replicon particles (VRPs) and 
lipid nanoparticle, both already successfully tested in vivo with many different vaccine 
candidates.  
The data obtained show that the rate of intracellular antigen expression driven by VRPs is faster 
compared to the expression driven by SAM encapsulated in LNPs. Moreover we observed a tight 
correlation between the onset of protein expression and MHC class I epitope presentation for 
both delivery systems, providing strong evidence that epitope presentation is temporally linked 
to antigen translation. Furthermore, after detection, no evident differences in the intracellular 
amount of protein antigen and in the level of epitope peptide were observed, assuming that the 
main difference between VRPs and LNPs is only related to the mechanism of cellular uptake. 
Then we applied this technology to quantify the SAM
 
encoded antigen in the muscle and lymph 
nodes of vaccinated mice at the site of injection, where this new type of vaccine are able to 
generate amount of antigen lower compare to the standard dose given by classical vaccines. 
Moreover, we move to an in vitro model of co-culture dendritic cells through, we were able to 
definitively confirm that this cells are not directly transfected by SAM but are able to up take 
antigen encoded by transfected myoblast cells.  
In this study we demonstrated the powerful use of Mass Spectrometry to better understand the 
mechanism of action of new kind of vaccines during the immune response.  
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INTRODUCTION 
 
1.1 History of nucleic acid vaccines 
 
Vaccination is one of the greatest historical medical successes, resulting in widespread 
prevention of morbidity and mortality of many infectious diseases across large human 
populations.  
In particular, since the beginning of the vaccine era, with the introduction of the smallpox 
vaccine more than two centuries ago, live-attenuated vaccines, have been effectively used in 
preventing infectious diseases and represent some of the safest and most effective vaccines in use 
today. 
By directly mimicking natural infection without causing disease, the attenuated virus vaccine 
strategy is attractive. They elicit a robust, broad and long-lived immune response without an a 
priori knowledge of the protective antigens of the pathogen. Moreover the attenuation of the 
pathogen often can be achieved empirically. 
The most recent versions of smallpox vaccines are based on a live, replicating bovine pathogen 
(Vaccinia virus) that confers protective immunity against disease caused by the human pathogen 
(Variola virus), and is safe for use in humans. The basis of protective immunity from live 
attenuated viral vaccines is now believed to be an induction of cross reactive antigen-specific 
antibody and T cell responses [1] as a result of limited viral infection launched by the delivery of 
an intact viral genome. 
Today, there are several licensed live attenuated vaccines, including those that protect against 
bacterial and viral diseases (polio, measles, mumps, rubella, influenza, yellow fever, rotavirus, 
chicken pox). 
However, the development of a live attenuated vaccine can become problematic when the 
organism does not replicate efficiently in cell culture (e.g., HCV) or when there is the potential 
reversion to a virulent strain (e.g., HIV, rabies). In addition, focus the immune system on certain 
immunogenic antigens of a given pathogen (e.g., hepatitis B surface antigen) might be a better 
choice. For this reason, subunit or recombinant protein-based vaccines are typically used but 
often require the co-administration of adjuvants or carriers to achieve a protective and long-
lasting efficacy due to the poor immunogenicity of protein antigens alone. 
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Nucleic acid-based vaccines have been developed as a means to combine the positive attributes 
of both live-attenuated and subunit vaccines. These include viral vectors such as those derived 
from adenoviruses or pox viruses, recombinant bacteria, plasmid DNA and RNA-based vaccines 
[2]. 
Bacterial and viral vectors can efficiently deliver nucleic acids into cells, similar to live 
attenuated organisms [2]. Vector genomes are engineered to express the antigen target(s) and in 
some cases, the vector may also be engineered to render the construct unable of replicating in the 
immunized host and to remove virulence factors responsible for pathogenicity. Vector-based 
vaccines are effective thanks to the efficient delivery of nucleic acid payload using pathways of 
cellular entry employed by the pathogen. In this way vectors mimic a live viral or bacterial 
infection, while reducing safety risks associated with live organisms.  
The two most common vector platforms, vaccinia [3] and adenovirus [4], have been shown in 
many human clinical trials to elicit antigen-specific antibody and T cell responses. However, a 
limitation of this approach resides in the anti-vector immunity, the neutralizing antibody 
responses directed toward viral proteins present on the surface of the vector or T cell responses 
against proteins expressed by the vector, reducing the effectiveness of the vaccine [5]. 
From this, nucleic acid-based vaccines have emerged as attractive alternative as they have the 
potential to combine the benefits of in situ expression of antigens with the safety of inactivated 
and subunit vaccines. Upon their discovery, more than 20 years ago, nucleic acid vaccines 
promised to be a safe and effective means to mimic immunization with a live organism vaccine 
[6]. They involve direct immunization with DNA or RNA encoding the antigen in situ, 
mimicking a true infection and inducing a specific immune response, only directed toward the 
antigen of interest. Both DNA and RNA-based vaccines do not generate anti-vector immunity, 
can be used for multiple doses, and are easy to produce, offering the potential to reducing 
manufacturing cost and to address newly emerging pathogens in a short time [7, 8]. 
 
1.1.1 DNA vaccines 
 
To date, the majority of preclinical and clinical studies using nucleic acid-based vaccines 
have been conducted with plasmid DNA (p-DNA) [9] and DNA-based viral vectors [10]. 
p-DNA vaccines are bacterial plasmid synthetized to express the encoded antigen following in 
vivo administration. The construction of bacterial plasmids with inserts encoding for vaccine is 
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based on the recombinant DNA technology. Once constructed, the vaccine-encoding plasmid is 
transformed into bacteria, for multiple plasmid copies replication. The plasmid DNA is then 
purified from the bacteria, by separating the circular plasmid from the much larger bacterial 
DNA and other bacterial impurities [9]. 
More than two decades of research and development have demonstrated the general utility of p-
DNA vaccines to elicit antibody and T cell-mediated protection in animal models of infectious 
and non-infectious diseases. However, despite intense development efforts, DNA-based vaccines 
still have some limitations due to the weak immunogenicity in humans compared to small animal 
models [9, 11] and for the potential risk of DNA integration into the host genome. For these 
reasons, RNA-based vaccines are considered a safer and more potent alternative to DNA 
vaccines. 
 
1.1.2 RNA vaccines 
 
Over the past decade, RNA-based vaccines are becoming a safer and more potent 
alternative to DNA for gene vaccination. RNA vaccines have some advantages compared to 
DNA-based vaccines. First, DNA needs to be delivered into the nucleus of host cells to induce 
the expression of the vaccine antigen, while RNA can be directly transcribed and translated into 
the target protein antigen into the cytoplasm, avoiding the limiting step of crossing the nuclear 
membrane and the potential risk of genome integration. 
Moreover, RNA is produced using a cell-free enzymatic transcription reaction, increasing 
production yields and avoiding safety concerns associated with the use of living organisms, as in 
the case of DNA vaccines [12]. 
Proof of concept for the utility of RNA in vaccination was demonstrated when intramuscular 
injection of mRNA in mice resulted in local production of the encoded protein and induction of a 
specific immune response against the encoded antigen [13]. Furthermore, mRNA vaccines can 
act as “self-adjuvant” by activating the RNA sensing machinery that usually provides the first 
barrier of defense against viral infections. Members of the Toll-Like Receptor family can sense 
exogenous RNA and activate innate immune responses involving mainly type I interferons 
(IFNs) [14].  
RNA vaccines are effective in eliciting both antigen-specific humoral and cellular responses in 
animal models of infectious and non-infectious diseases. Moreover, pre-clinical data have 
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demonstrated the safety profile of mRNA-based cancer vaccines and their capability to induce 
tumor antigen-specific immune responses [12]. 
Currently, there are two major types of mRNA vaccines, distinguished by the translational 
capacity of the RNA: conventional non-amplifying mRNA molecules and self-amplifying 
mRNA.  
 
Fig. 1. Structural elements of RNA-based vaccines. Schematic illustration of a conventional non-
amplifying mRNA containing the cap structure, the 5’ UTR region, an open reading frame encoding the 
gene of interest (GOI), 3’ UTR and a poly(A) tail, and of a self-amplifying mRNA derived from an 
alphavirus genome, containing the basic elements described above, an ORF encoding four non-structural 
proteins (nsP1-4), and a sub-genomic promoter upstream to the GOI [15]. (Adapted from Nucleic acid 
vaccines: prospects for non-viral of m-RNA vaccines delivery Expert Opin. Drug Deliv., 2014, Deering 
R.P.)  
 
 
 
Non-amplifying mRNA molecules consist of five key elements critical in the life cycle and 
expression of mRNA: a cap structure (m7Gp3N (N: any nucleotide)), a 5’ untranslated region (5’ 
UTR) situated immediately upstream of the translation initiation codon; an open reading frame 
(ORF) that encodes a gene of interest (GOI), a 3’ untranslated region (3’ UTR), and the tail of 
100–250 adenosine residues (poly (A) tail). All five elements in the mRNA construct control the 
synthesis of proteins by influencing mRNA stability, accessibility to ribosomes, and 
circularization and interaction with the translation machinery [12]. 
However, non-amplifying mRNAs are poorly immunogenic in vivo [16], probably because of 
their short half-life resulting in brief time of antigen expression. To extend the duration and the 
magnitude of antigen expression, self-amplifying mRNAs were developed.  
 6 
 
Self-amplifying mRNAs, are derived from positive or negative-stranded RNA viruses like 
alphaviruses (Sindibis, Semliki Forest, and Venezuelan equine encephalitis viruses) or 
flaviviruses [17-19]. They contain a large ORF encoding four nonstructural viral proteins (nsP1-
4) and a sub-genomic promoter upstream of the genes encoding for the proteins of interest that 
replaces the genes encoding the viral structural proteins required to make an infectious virus 
particle (Figure 1). Self-amplifying mRNAs derived from different RNA viruses differ with 
regard to levels and duration of heterologous gene expression, allowing generation of a versatile 
toolbox for vaccine applications [57]. 
After delivery into the cytosol of a cell, the released mRNA is translationally competent, and the 
engagement with the host cell ribosome produces the four functional components of RNA-
dependent RNA polymerase (RDRP) or viral genome replication apparatus: nsP1, nsP2, nsP3, 
and nsp4. Translated nsPs form replication factories on the surface of intracellular membranes 
and transcribe full-length negative-strand copies from the input mRNA. This negative-strand 
copy then serves as a template for two positive-strand RNA molecules: the genomic mRNA and 
a shorter, co-linear sub-genomic mRNA. 
This sub-genomic mRNA (also known as the 26S RNA), is transcribed at extremely high levels, 
permitting the amplification of mRNA encoding the vaccine antigen.  
Self-amplifying mRNA vaccines have attractive features that are lacking in non-amplifying 
mRNA vaccines, such as the auto replicative ability resulting in high levels of expression of the 
encoded vaccine antigen in host cells, regardless of cell division. In addition, dsRNA molecules 
that are produced during RNA replication are known to be potent stimulators of innate immunity, 
resulting in the induction of enhanced immune response [20, 21]. 
RNA replicons are effective in eliciting humoral and cell-mediated immune responses in 
different animal models, including mice [16], non-human primates [22], and humans [23], and 
against several target diseases. One potential disadvantage of RNA-based vaccines is their 
instability that could be improved by appropriate delivery systems. In fact, high doses of naked 
RNAs are necessary for eliciting an immunological response in vivo. Therefore, one of the most 
important challenges for RNA-based vaccines is finding effective delivery methods able to 
prevent RNA enzymatic degradation and to facilitate the transfection of host cells.  
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A recent advancement in self-amplifying RNA vaccines is the use of a synthetic delivery system 
including inorganic particles, polymeric-based, cationic lipid-based vectors, and physical 
methods such as electroporation and gene gun delivery [24].  
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1.2 Delivery of Self-amplifying mRNA vaccines 
 
1.2.1 Viral delivery system  
 
RNA replicons can be packaged into virus-like particles derived from Alphaviruses, by 
supplying the structural proteins in trans in cell culture.  
Alphaviruses are positive-sense RNA viruses that belong to the largest genus of the Togaviridae 
family.  
The alphavirus particle is a 70 nm diameter icosahedron, containing a single-strand, positive-
sense RNA genome that is capped and polyadenylated. The genome is approximately 11.5 
kilobases and is associated to the capsid protein (C), producing a nucleocapsid core that is 
enveloped in a cell-derived lipid bilayer embedded with E1 and E2 glycoproteins that provide 
cell targeting and endosomal escape functions to the virus. 
To date is known that alphaviruses enter into cells by receptor-mediated endocytosis, followed 
by the fusion of the viral membrane to the cell membrane in the endolysosomes. This process 
allows the release of RNA and nucleocapsid into the host cell cytosol. 
However, recent works demonstrate that alphavirus entry is independent to endocytosis, 
suggesting that viral may entry directly through plasma membrane (reviewed in [25]). 
In several studies alphaviruses have been adapted as vaccine vectors [26], in the simplest case, 
this is accomplished by replacing the structural alphavirus protein genes with a heterologous 
gene of interest (GOI). The resulting mRNA, called replicon, is capable, when introduced into 
the cytoplasm of host cells, to replicate and to express the heterologous gene; however, since it 
does not encode the alphavirus capsid or glycoprotein genes, it is unable of forming effective 
viral particles or spreading to adjacent cells.  
Moreover, if these replicons are introduced into a cell in which the capsid and glycoprotein genes 
are expressed in trans, virus replicon particles (VRPs) with identical protein and lipid structure 
to wild-type alphaviruses and that encapsulate replicon RNA in place of a normal alphavirus 
genome are produced. VRPs are capable of infecting cultured cells and cells in inoculated 
animals allow the expression of GOI, also in this case they are incapable of producing a viral 
particle and spreading cell-to-cell due to the lack of structural protein genes. VRP-based vaccine 
candidates have been extensively tested against bacterial and viral infections, in a variety of 
small animal and primate models [27].  
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Although both preclinical and clinical data for viral delivery of self-amplifying mRNA are 
encouraging, this technology requires the electroporation and the use of large-volume of 
formulations containing the genetic elements into cells in culture, clearly not applicable to 
industrial-scale production. In addition, during the production of VRPs in cells containing both 
replicon and helper RNAs, there is the possibility that recombination or co-packaging of 
replicons and helper RNAs could bring to the assembling of infective virions. 
If on one side, viral particle delivery of replicons is the most efficient means to deliver nucleic 
acids into cells, on the other side, it is limited by complicated manufacturing, safety concern and 
anti-vector immunity [28]. To avoid these limitations and to provide protection from RNA 
degradation, non-viral delivery of replicons has been explored in order to develop an effective 
and safer vaccine. 
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1.2.2 Non-viral delivery system: SAM
 
 vaccines 
 
Recently, Geall et al. [29] described the non-viral delivery of self-amplifying mRNAs. 
The SAM vaccine platform is based on a synthetic, self-amplifying RNA derived from an 
engineered alphavirus genome containing the alphavirus replication machinery, but lacking the 
viral structural genes required to produce infectious alphavirus particles. To be commercially 
competitive as a technology platform, mRNA based vaccines must induce the same 
immunogenicity of viral vector-based vaccines, at doses of RNA that are not cost prohibitive. 
For this purpose, Geall and colleagues took advantage of the recent innovations in systemic 
delivery of short interfering RNA [30] to develop a synthetic lipid nanoparticle (LNP) 
formulation for SAM replicons [29]. Cationic lipids and mRNA are mixed together to obtain 
stable particles that prevent RNA enzymatic degradation and deliver the mRNA into host cells 
by interacting with the negatively charged cell membrane. Once in the cytoplasm, the RNA 
polymerase, encoded by the non-structural genes of the viral replicon, is expressed and it 
produces a negative-sense copy of the genome that is used as template for the amplification of 
the genome, as well as for the transcription of the sub-genomic mRNA encoding the vaccine 
antigen [31] (Figure 2).  
Fig. 2. Schematic illustration of the replication and expression steps of self-amplifying RNA after 
delivery to a mammalian host cell.  
The RNA encapsulated by lipid nanoparticles is delivered in the cytoplasm of a host cell where the RNA 
polymerase encoded by the non-structural genes is expressed and drives the amplification of the RNA as 
well as the transcription of the sub-genomic mRNA encoding the vaccine antigens (Adapted from: A 
cationic Nanoemulsion for the delivery of next generation RNA vaccines. Mol Ther, 2014).  
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The LNP formulation enhances the potency of the self-amplifying RNA, eliciting potent and 
protective immune responses in preclinical models of infection that are comparable to a viral 
delivery system, but without the inherent limitations of viral vectors [29]. Preclinical proof of 
concept for SAM vaccines has been achieved so far in different animal models (mouse, cotton 
rats, ferrets, rabbits, non-human primates), and against several pathogens like respiratory 
syncytial virus, influenza virus, human immunodeficiency virus, cytomegalovirus, Ebola and 
Plasmodium [8, 24, 29, 32]. Moreover, the SAM vaccine platform shows several important 
advantages: synthetic and highly scalable production process; robust, generic means to 
manufacture vaccines against many pathogen targets; avoidance of anti-vector immunity and 
safety issues associated with genome integration; high immunogenicity (both humoral and 
cellular) with low RNA doses [33].  
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1.3 The immune system  
 
The immune system is a remarkably versatile defense system that has evolved to protect 
animals from invading pathogenic microorganisms and cancer.  
It is able to generate an enormous variety of cells and molecules capable of specifically 
recognize and eliminate an apparently limitless variety of foreign invaders. 
Functionally, an immune response can be divided into two related activities: recognition and 
response [30]. 
Immune recognition is remarkable for its specificity. The immune system is able to recognize 
subtle chemical differences that distinguish one foreign pathogen from another. Furthermore, the 
system is able to discriminate between foreign molecules and self-cells and proteins. Once a 
foreign organism has been recognized, the immune system recruits cells and molecules to mount 
an appropriate response, called effector response, to eliminate or neutralize the foreign organism. 
In this way, the system is able to convert the initial recognition event into a variety of effector 
responses, each uniquely suited for eliminating a particular type of pathogen.  
Immunity, the state of protection from infectious disease, has both a less specific and more 
specific component. The less specific component, innate immunity, provides the first line of 
defense against infection. Most components of innate immunity are present before the onset of 
infection and constitute a set of disease-resistance mechanisms that are not specific to a 
particular pathogen but that include cellular and molecular components that recognize classes of 
molecules peculiar to frequently encountered pathogens.  
The principal components of innate immunity are physical and chemical barriers, such as 
epithelia, phagocytic cells (neutrophils, monocytes and macrophages), dendritic cells (DCs), 
natural killer (NK) cells, and blood proteins, including members of the complement system and 
other mediators of inflammation, such as chemokines and cytokines that regulate and coordinate 
many of the activities of the cells of the immune system. All these mechanisms of innate 
immunity cooperate to recognize and react against pathogens [34]. 
In contrast to the broad reactivity of the innate immune, which is uniform in all members of a 
species, the adaptive immunity (the specific one), is not activated as long as the antigenic 
challenge penetrate into the organism and was recognized. 
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An adaptive immune response involves two major groups of cells: lymphocytes and antigen-
presenting cells (APC). Lymphocytes belong to the white blood cells produced in the bone 
marrow by the process of hematopoiesis. Lymphocytes leave the bone marrow, circulate in the 
blood and lymphatic system, and reside in various lymphoid organs. Because they produce and 
display antigen binding cell-surface receptors, lymphocytes mediate the defining immunologic 
attributes of specificity, diversity, memory, and self/non-self-recognition. The two major 
populations of lymphocytes and are T cells and B cells (Figure 3). 
T lymphocytes arise in the bone marrow and migrate to the thymus gland to mature. During their 
maturation T cells became able to express a unique antigen-binding molecule, called the T-cell 
receptor, on its membrane that can recognize only one fragment (peptides) of protein or 
glycoprotein called antigenic determinant or epitopes that is bound to cell-membrane proteins 
called major histocompatibility complex (MHC) molecules. There are two subpopulations of T 
cells: T helper (TH) and T cytotoxic (TC). 
When a naïve TH cell recognizes and interacts with an antigen-MHC molecule complex, the cell 
is activated and becomes an effector that secretes various growth factors and cytokines. These 
cytokines play an important role on the activating of B cells, TC cells, macrophages, and various 
other cells that participate in the immune response. Under the influence of TH-derived cytokines, 
a TC cell that recognizes an antigen-MHC molecule complex proliferates and differentiates into 
an effector cell called a Cytotoxic T lymphocyte (CTL). In contrast to the TC cell, the CTL 
generally does not secrete many cytokines but exhibits cell-killing or cytotoxic activity. The CTL 
has a vital function in monitoring the cells of the body and eliminating any that display antigen, 
such as virus-infected cells, tumor cells, and cells of a foreign tissue graft.  
B lymphocytes mature into the bone marrow and express a unique antigen-binding receptor that 
is a membrane-bound antibody molecule. When a naïve B cell first encounters the antigen that 
matches its membrane bound antibody, the binding of the antigen to the antibody causes the cell 
to divide rapidly; its progeny differentiates into memory B cells and effector B cells called 
plasma cells. Memory B cells have a longer life than naïve cells, and they express the same 
membrane-bound antibody as their parent B cell. Plasma cells produce the antibody in a form 
that can be secreted that act as major effector molecules of humoral immunity. 
 
 14 
 
 
Fig. 3. Humoral and cell mediated branches of the immune system.  
In the humoral response, B cells interact with antigen and then differentiate into antibody-secreting 
plasma cells. The secreted antibodies bind to the antigen and facilitate its clearance from the body. In the 
cell-mediated response, various sub-populations of T cells recognize antigen presented on self-cells. TH 
cells respond to antigen by producing cytokines. TC cells respond to antigen by developing into cytotoxic 
T lymphocytes (CTLs), which mediate killing of altered self-cells (virus-infected cells). (Adapted from 
Fundamental Immunology, Vaccines (Chapter 43), William E. Paul). 
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1.3.1 Antigen presenting cells (APCs) 
 
Activation of both the humoral and cell-mediated branches of the immune system 
requires cytokines produced by TH cells. To carefully ensure regulated activation of TH cells, 
they can recognize only antigens that are displayed with the MHC molecules on the surface of 
antigen-presenting cells (APCs).  
These specialized cells, which include macrophages, B lymphocytes, and dendritic cells, are 
distinguished by the expression of MHC molecules on their membranes and for the ability to 
deliver a stimulatory signal necessary for TH-cell activation.  
 
1.3.2 The Major Histocompatibility Molecules and Antigenic Peptide Epitopes 
 
Major histocompatibility (MHC) molecules are a large genetic complex with multiple 
loci that encode for two major classes of membrane-bound glycoproteins: class I and II.  
MHC class I and class II molecules are similar in function: they present peptides to the surface of 
CD8
+
 and CD4
+
 T cell respectively, the choice between the two mechanisms appears to be 
determined by the entry route of the antigen into a cell.  
Endogenous antigens, also produce within the host cell as viral proteins synthesized in virus-
infected host cells or unique proteins synthesized by cancerous cells, are processed by MHC 
class I molecules, while exogenous antigens are captured by endocytosis and processed by MHC 
class II molecules.  
Endogenous, normal and abnormal proteins were degraded by the proteasome into peptide 
fragments. These fragments are translocated to the endoplasmic reticulum (ER) through a 
peptide transporter called Transporter Associated with antigen Processing (TAP) that is 
embedded in the ER membrane and allows the access to MHC class I molecules.  
In the ER, MHC class I molecules presents a heterodimer form, constituted by a polymorphic 
heavy chain and a light chain called β2-microglobulin (β2-m) in which the peptide is the third 
component required for the stability. Without peptides, MHC class I molecules are stabilized by 
ER chaperone as Calreticulin, ERp57, protein disulfide isomerase (PDI) and Tapasin. TAP forms 
the peptide-loading complex in the ER, interacting with Tapasin and promotes MHC I binding of 
peptides with a slow off rate, thereby helping to shape the repertoire of presented peptides.  
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These are peptides of a very specific length of eight to ten amino acids with appropriate anchor 
residues. Peptides that are too long can be trimmed by an ER-resident aminopeptidase, ERAP1, 
before consideration by MHC I molecules that are either in the peptide-loading complex or 
associating with another Tapasin look-like chaperone in the ER called TAPBPR. 
TAPBPR binds peptides longer than eight or nine residues, but not shorter ones, triggers a 
conformational change in ERAP1 that activates its hydrolysis. Through this mechanism, ERAP1 
trims most peptides down to eight or nine residues, corresponding to the size needed for optimal 
binding to MHC I molecules.  
Peptides that are unable to bind an MHC I molecule are ultimately translocated back into the 
cytosol for degradation.  
Peptides should be considered the third subunit of MHC I molecules, required to stabilize the 
complex, MHC class I molecules fully assembled, leave the ER for presentation at the cell 
surface of all nucleated cells to CD8
+
 T cells. These cytotoxic T cells attack and kill cells 
displaying the antigen MHC class I complexes for which their receptors are specific. MHC class 
I molecules that never bind proper peptides were finally degraded by a ER-associated protein 
degradation system (ERAD) [34]. 
While MHC class I molecules are ubiquitously expressed, MHC class II molecules are primarily 
expressed by professional APCs, such as DCs, macrophages and B cells. MHC class II presents 
peptide fragments that are generally larger than those presented by MHC class I, because the 
peptide-binding groove of MHC class II is open, allowing peptides to extend out of this site. The 
MHC class II-associated peptides are derived from extracellular proteins and from self-proteins 
that are degraded in the endosomal pathway (Figure 4) [35]. During their assembly in the ER, 
MHC class II molecules are associated with an invariant chain Ii, which acts as a pseudo-peptide 
by filling the MHC class II peptide-binding groove and targets MHC II molecules into the 
endosomal pathway [36-38]. 
The resulting Ii-MHC class II complex is transported to a late endosomal compartment termed 
MHC class II compartment (MIIC), where Ii is digested, leaving a fragment of invariant chain 
(called CLIP) in the peptide-binding groove [39]. CLIP fragment has to be exchanged for higher-
affinity peptides, derived from protein degradation in the endosomal pathway, with the help of a 
dedicated MHC class II-like chaperone called H2-DM [40]. The structure of H2-DM in 
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association with MHC II reveals that this chaperone locally opens the groove to release CLIP 
leaving the proper peptide fragments in the MHC class II peptide-binding groove [41]. 
After some period of residence in MIIC, MHC II molecules move to the plasma membrane either 
via vesicular transport or in the form of tubules [42-44]. Since the targeting information in the 
invariant chain has been removed after its degradation in MIIC, MHC II molecules can stably 
reside on the plasma membrane.  
MHC II molecules on dendritic cells present antigen to naïve CD4+ T cell to activate them; later 
they participate in the interaction of B cells and macrophages with these specific CD4 effector T 
cells. 
 
 
Fig. 4. Processing and presentation of exogenous and endogenous antigens by MHC Complexes.  
(A) Exogenous antigen is ingested by endocytosis or phagocytosis and then enters the endosomal 
processing pathway. Here, within an acidic environment, the antigen is degraded into small peptides, 
which then are presented with class II MHC molecules on the membrane of the antigen-presenting cell. 
(B) Endogenous antigen, which is produced within the cell itself (e.g., in a virus infected cell), is 
degraded within the cytoplasm into peptides, which move into the endoplasmic reticulum, where they 
bind to MHC class I molecules. The peptide–class I MHC complexes then move through the Golgi 
complex to the cell surface (Adapted from Immunology 5e, Golsby 2012). 
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1.4 Quantitation of antigen presentation  
 
Cellular immunity is driven by the interaction of T cell receptors (TCRs) on T cells 
recognizing peptides, presented on the surface of cells in complex with molecules encoded by 
the major histocompatibility complex (MHC). The total array of MHC-bound peptides (p-MHC), 
presented at the surface of cells (the immune-peptidome) for recognition by T cells, is likely in 
the order of tens to hundreds of thousands of complexes.  
While the precise relationship between the abundance of a given T cell ligand, its half-life on the 
cell surface and immune outcome remain to be fully elucidated, simple models suggest that such 
factors define the magnitude of the immune response to a given T cell epitope. The ability to 
accurately, rapidly and comprehensively quantify antigen presentation is therefore crucial to 
develop new models to predict immunogenicity and immune outcomes.  
Traditionally, immunologists have measured immune out-puts such as antibody titers and 
cytokine levels using techniques such as ELISpot and ELISA assays, however despite 
technological advancements in this field, systematic and accurate epitope identification and 
quantitation on the surface of cells has remain a challenge in quantitative system immunology. 
To date, the use of T cell lines, clones and hybridomas to study antigen presentation has been 
widely reported in the literature [45]. These biological reagents can be generated or isolated from 
immune hosts and expanded in vitro for semi-quantitative assays of antigen presentation. In this 
way many T cell hybridomas can recognize their pMHC in a co-stimulation assay, making them 
a useful tool to study antigen processing and presentation without such signals that can influence 
the responsiveness of primary T cells.  
Moreover the use of antibodies to quantitate T cell epitopes has also been widespread by the 
pioneering studies of Unanue and colleagues that developed and use of ELISA with anti-peptide 
antibodies to estimate the lysozyme peptide contents extracted from I-A
k
 MHC II molecules. 
Alternatively, m-Abs generated with TCR-like reactivity specific for particular pMHCs are a 
more attractive option. However all these approaches remain time consuming to generate and 
their sensitivity and specificity cannot be determined with accuracy [46]. 
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1.5 Contribution of Mass Spectrometry-based proteomics in 
immunopeptidome. 
 
Over the past few decades, Mass Spectrometry became the core technology for the 
analysis of MHC ligandome. 
After immunoaffinity purification of detergent-solubilized peptides-MHC complexes, followed 
by acid elution of peptides, liquid chromatography-mass spectrometry could be apply to gain 
qualitative and quantitative insight into the MHC-presented peptide repertoire. In fact, with this 
approach, both the intact peptide (precursor ion) and its fragmentation spectra (product ions) can 
be determined with high accuracy providing unambiguous identification of epitope sequences. 
This approach has been used to quantitate peptides associated with MHC class I [47] and II 
molecules [48], overcoming the greater complexity and heterogeneity of class II bound species.  
In a recent study conducted by Ternette et al., quantitative mass spectrometry approach was used 
to monitor the abundance of several immunogenic peptide epitopes, examining in detail the 
kinetics of the HLA Class I associated immunopeptidome of APCs after infection with a viral 
vector encoding a HIV vaccine construct. [47]. 
This study demonstrated the power of quantitative MS for the identification and quantitation of 
HLA class I-associated peptides for T-cell epitope discovery and its use to optimize and inform 
vaccine design [47].  
Moreover, while the above technique can provide relative quantitation and estimates of epitope 
copy number in cell surface, the inclusion of stable isotope labeled peptide standards provides an 
absolute quantitation [49, 50]. In this case the quantitation is achieved through the parallel 
detection of the light (native) and isotopically labeled (heavy) peptides, both having matching 
liquid chromatographic separation due to identical sequence, followed by a comparison of their 
intensity profiles.  
The method, known as Selected Reaction Monitoring (SRM) or Multiple Reaction Monitoring 
(MRM), is employed worldwide as the benchmark technique for highly sensitive quantitation of 
peptides isolated from biological samples and is based upon the precise knowledge of a peptide 
mass coupled to its unique fragmentation spectra.  
SRM has been used to quantitate selected MHC class I [51-53]  and class II-bound peptides [54]. 
In particular, in a study by Croft et al., SRM was used to perform MHC class I epitope 
quantitation in vitro and in vivo utilizing the H-2K
b
-SIINFEKL model system to detect and 
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quantitate SIINFEKL presentation. This was achieved for cell lines expressing the intact parental 
ovalbumin antigen [53], on cells infected with recombinant viruses expressing ovalbumin as a 
surrogate of viral antigen [51] and during presentation of ovalbumin in vivo [53]. In these studies 
SIINFEKL was detected in as low as just a few copies per cell in vivo, to several hundred copies 
on APCs transfected with ovalbumin-expressing constructs through to tens of thousands of 
copies when recombinant vaccinia virus encoding ovalbumin was used to infect APC.  
SRM was also considered the tool of choice to investigate the endogenous MHC class II peptides 
presentation. In work by Bozzacco et al., SRM analysis was used to perform a qualitative and 
quantitative profile of the endogenous MHC class II peptides presented in vivo by mouse spleen 
dendritic cells, and B cells allowing a direct comparison between to these two types of immune 
cells. In this study is shown as the endogenous source proteins for the MHC II bound peptides 
identified on DCs and B cells are localized among different cellular compartments and reflects 
the distinct immune functions of the two cell types [54].  
In particular, for DCs, epitope peptides derive from proteins involved in antigen presentation [55, 
56], in contrast to B cells where peptides derive from proteins involved in cell to cell signaling 
and DNA recombination and repair, required during antibody production and immunoglobulin 
class switching [57-59]. 
Moreover, the simultaneous quantitation of the source protein antigen and the peptides bound on 
MHC molecules facilitates understanding the relationship between the presence of antigen and 
the following generation of the specific peptide epitopes. Also in this case, mass spectrometry 
plays a key role being used to identify and quantify simultaneously both proteins and epitope 
peptides. In fact mass spectrometry has the capability to delve deep into cellular proteome, 
obtaining information related to proteins expressed across large dynamic ranges where highly 
sensitive technique for their detection and quantification are required.  
In this contest a work by Purcell et al., defines the powerful use of SRM to simultaneously 
quantify the presentation of eight Vaccinia virus peptide-MHC class I complexes on infected 
cells and the amount of their source antigen at multiple time point after infection, in order to 
dissect anti-viral immunity. This study showed the tight correlation between onset of protein 
expression and epitope display for most antigens provides the strongest support that antigen 
presentation is largely linked to protein translation and not to later degradation of antigens during 
virus infection.  
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1.5.1 Targeted proteomics technique: Selected reaction monitoring-and Parallel 
reaction monitoring 
 
The ability to detect and quantify proteins with high precision across multiple samples is 
an essential task in biological and biomedical research. In this field, SRM has emerged as a 
promising technique for such precise quantification of targeted proteins [60-62]. Originally 
applied to the measurement of small molecules (such as metabolites or drugs [63]), SRM is a 
mass spectrometry technique involved in the detection and quantification of specific, 
predetermined analytes with known fragmentation pattern in complex backgrounds. Whit this 
purpose, SRM exploits the unique capability of triple quadrupole (QQQ) mass spectrometers 
[64], to act as mass filters and to selectively monitor a specific analyte molecular ion and one or 
several fragment ions generated from the analyte by collisional dissociation [64]. 
The number of such fragment ions that reach the detector is counted over time Figure 5, 
resulting in a chromatographic trace with retention time and signal intensity as coordinates. 
Several such precursor–fragment ion pairs, termed SRM transitions, can be sequentially and 
repeatedly measured at a periodicity that is fast compared to the analyte chromatographic elution, 
yielding chromatographic peaks for each transition that allow for the concurrent quantification of 
multiple analytes. When applied to proteomics, SRM measures peptides produced by the 
enzymatic digestion of a proteome as surrogates of the corresponding proteins. Molecular ions 
within a mass range centered around the mass of the targeted peptide are selected in the first 
mass analyzer (Q1), fragmented at the peptide bonds by collision-activated dissociation (in Q2) 
and one or several of the fragment ions uniquely derived from the targeted peptide are measured 
by the second analyzer (Q3) [60, 65].  
 
Fig.5. Selected Reaction Monitoring technique. Molecular ions of a specific analyte are selected in Q1 
and fragmented in Q2. A specific fragment ion from the targeted analyte is selected in Q3 and guided to 
the detector. 
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In contrast to conventional shotgun proteomic studies, SRM requires a more complex workflow.  
An SRM-based proteomic experiment starts with the identification of a list of target proteins, 
followed by the selection of peptides, called proteotypic peptides, which are uniquely associated 
to the protein of interest [66, 67]. Then, for each proteotypic peptide, a set of suitable SRM 
transitions were identified and validated (described in 3.1.4.1 Results section). Finally, the assay 
was applied for the detection and quantification of the specific proteins (Figure 6).  
First desirable target peptide, uniquely associated to target protein and easily detectable by mass 
spectrometry have to be selected. The selection of peptides with favorable mass spectrometry 
features is crucial and determines the sensitivity of the assay. In an ideal case, the target proteins 
are available as purified products, and the mass spectrometry signal-response of all their tryptic 
peptides can be directly tested via LC-MS/MS. In general, short hydrophilic and long 
hydrophobic peptides should be avoided, whereas fully tryptic peptides with an average length of 
ten amino acids, devoid of residues prone to artefactual or post-translational modifications 
should be targeted [65].  
Moreover the fragmentation patterns (fragment ions) for each peptides (precursor ions), that 
provide the highest signal intensity and lowest level of interfering signal were selected to define 
the specific SRM transition. In fact for the quantification of a protein in SRM experiment using a 
QQQ instrument, it is essential to select the specific m/z value for the first (Q1) and third 
quadrupole (Q3) in order to identify the peptide parent ions and the daughter ions.  
The collision energy (CE) value associated for the ion fragmentation in Q2 is then another 
fundamental value that has also been optimized individually for each peptide in order to provide 
the best signal intensity. This is obtained using a CE step variations analysis, monitoring the 
corresponding obtained peak area intensity [65, 68].  
 
Fig. 6. Workflow of a SRM-based proteomic experiments  
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Finally the precise and absolute quantitation of the target proteins is achieved through the 
parallel detection and comparison of the intensity of native peptides and the isotopically labeled 
(heavy) ones, both having identical liquid chromatographic separation due to same sequence. 
Thus, the success of SRM is dependent on the transitions of the target peptides that are pre-
selected and used for monitoring during data acquisition: selecting the best possible transitions 
for the target proteins results in reliable quantification. 
For this reason, SRM requires significant effort in building a data acquisition method for a set of 
candidate proteins and, in order to select the best set of peptides and transitions, multiple 
iterations and optimizations may be required  
Recent studies have shown that a same targeted experiments known as Parallel Reaction 
Monitoring (PRM) can also be performed on hybrid quadrupole-Orbitrap (q-OT) or quadrupole 
time-of-flight (q-TOF) mass spectrometers.[69-72] The Orbitrap in a q-OT replaces the third 
quadrupole (Q3) mass analyzer of a QQQ instrument. Studies using SRM and PRM have shown 
that both these targeted methods have comparable sensitivity with similar linearity, dynamic 
range, precision, and repeatability for quantification of proteins.[73] However, PRM has certain 
advantages over SRM, such as it is relatively easier to build the data acquisition method because 
a priori selection of target transitions is not required. Furthermore, PRM provides high 
specificity because the MS/MS data is acquired in high resolution mode that can separate co-
isolated background ions from the target peptide ions. In SRM, only three to five transitions are 
monitored, whereas in PRM a full MS/MS spectra is acquired that contains all the potential 
product ions and confirms identity of the target peptide. 
The development and implementation of higher energy collision-induced dissociation (HCD) 
fragmentation enabled MS/MS spectra to be acquired in the Orbitrap analyzer with high 
resolution and high mass accuracy. HCD is a beam-type collisional dissociation similar to the 
dissociation achieved in triple quadrupole mass spectrometers, as well as in quadrupole time-of-
flight (QTOF) mass spectrometers.  
An advantage of the q-OT mass spectrometer is that both discovery and targeted experiments can 
be performed on the same instrument. This makes it easier to transfer instrumental parameters 
(e.g., collision energy, quadrupole isolation window, automatic gain control, retention time etc.) 
between the two data acquisition methods.  
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In PRM, when performed in q-OT, a predefined precursor ion is selected in the quadrupole and 
transferred via the C-trap to the HCD cell for fragmentation. The C-trap can fill with ions for 
longer times, increasing signal-to-noise ratio of the ions measured in the Orbitrap. [70, 74] 
From the HCD cell, fragment ions are transferred back to the C-trap and eventually injected and 
analyzed in the Orbitrap mass analyzer (Figure 7). Since full MS/MS spectra of the targeted 
peptides are acquired with high resolution and high mass accuracy, a PRM-based targeted 
method of protein quantification is highly selective and specific.[69, 70] Moreover to further 
improve data acquisition efficiency, also in this type of analysis, isotopically-labeled internal 
standards can be used to drive PRM acquisitions of the endogenous peptides (IS-PRM) and 
perform the absolute quantitation.[75] 
 
Fig.7. Parallel reaction monitoring technique. PRM workflow. 
In PRM, a target precursor ion is isolated in the quadrupole analyzer and fragmented in the HCD cell; the 
fragment ions are then detected in the Orbitrap mass analyzer. PRM generates high resolution, full 
MS/MS data. During data processing, the MS/MS spectrum is used for the identification of the peptide 
and a subsets of fragment ions with highest intensities in the MS/MS spectrum are used for quantification 
using the internal standard (IS) approach (Adapted from Parallel Reaction Monitoring: A Targeted 
Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry, 
International journal of molecular science, 2015). 
 
 
 
For its features, SRM and PRM are similar to Western blotting analysis; used for the 
identification and quantification of specific known set of proteins in a complex background. 
However, the methods differ substantially in their implementation, the reliability of the resulting 
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A Western blotting assay essentially depends on the specificity of the antibody used [77, 78], in 
contrast to an SRM or PRM assays that depends on multiple parameters, such as the retention 
time, the mass-to-charge ratio of the parent ions and daughter fragment ions of the targeted 
peptide, and the relative signal intensities of the detected fragment signals [68]. 
Moreover the quality of quantitative data obtained is very different, quantification by Western 
blotting is based on the intensity of a band obtain by the reaction of specific antibody that may be 
poorly characterized, moreover a reference sample is not always available to test the 
performance of the assay. In contrast, mass spectrometry targeted assays depend on isotopically 
labeled reference peptides, the quality of which can be always verified in a fragment ion 
spectrum. Moreover, multiple independent peptides are monitored simultaneously to quantify a 
specific protein, which signals are integrated into a composite score indicating the protein 
quantity.  
SRM and PRM are then consider to date the key technologies to delve deep into a proteome, 
obtained a precise and absolute quantitative information related to protein or more proteins 
expressed across large dynamic range and applied to obtain sensitive data from different and 
very complex biological background as cellular lysate and tissue in different filed as biology, 
clinical and to study protein interaction and modification. 
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RATIONALE AND AIM 
 
Nucleic acid-based vaccines such as viral vector, plasmid DNA and mRNA are being 
developed as a means to overcome the limitations of both live-attenuated and subunit vaccines. 
However, viral vectors and DNA vaccines still have some constriction. Efficiency of 
recombinant viral vector technologies is hampered by anti-vector immunity, complex production, 
and safety concerns, whereas DNA-based vaccines require multiple administrations and high 
doses to overcome the low immunogenicity in humans. Despite significant advancements, none 
of these vaccines has been licensed to date. Among them, Self-amplifying mRNA vaccines are 
emerging as a novel class of nucleic acid. They preclude safety concerns about DNA integration 
into the host genome and can be directly translated in the host cell cytoplasm, circumventing the 
complications associated with nuclear transport. Moreover, the simple cell-free, in vitro synthesis 
of RNA avoids the manufacturing issues associated with viral vectors.  
In particular, non-viral delivery of self-amplifying mRNAs (SAM platform), derived from a 
modified alphavirus genome, was successfully applied to different pathogens, in different animal 
models and was confirmed to be able to elicit a very potent immune response due to broad 
antigen expression and to their intrinsic adjuvant activity [24, 29, 79]. 
To date, most of the analysis of SAM vaccines encoded antigen expression and localization, in 
an in vivo model system based on reporter genes as Firefly Luciferase or Secrete Alkaline 
Phosphatase (SEAP), where bioluminescence or chemoluminescence were the monitored 
parameters [24]. In that assay bioluminescence intensity induced by LNP/RNA, was comparable 
to the bioluminescence induced by a viral delivery system. In particular mice injected with 
LNP/RNA showed measurable bioluminescence that was already detected on day 3, peak on day 
7 and decrease to background by day 63 post immunizations. This kinetic contrasted with those 
observed by the same RNA but delivered by VRPs where bioluminescence was observed at day 
3 compared to LNP/RNA, but with a much more rapid decay that reached background level 
already by day 28. 
Moreover little has been described about the mechanism of action of these vaccines. 
Nevertheless it seems that myocyte cells and not immune cells (antigen presenting cells) are the 
predominant cell type transfected within the injection site at time of vaccination [24]. Recent 
studies demonstrate that in vivo priming of MHC class-I restricted CD8
+
 T cells following SAM 
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immunization involves bone marrow-derived professional APCs. Therefore, myocytes can only 
provide an antigen source for the induction of a MHC class-I restricted CD8
+
 T cell response by 
APCs [80].  
The aim of this study is to provide a better understanding of the molecular mechanism involved 
in the antigen expression step and in the endogenous intracellular processing on MHC class I 
molecule during SAM vaccination. 
Quantitative mass spectrometry (MS) approach based on Selected Reaction Monitoring (SRM) is 
used, rapid advances in MS instrumentation enabled both the relative and absolute quantification 
of specific set of proteins. For these reasons, we focused our attention to the expression of 
antigenically conserved protein Nucleoprotein (NP) from Influenza virus setting up an in vitro 
cellular model based on myoblast cell line C2C12, where SRM was applied to investigate the 
quantitative correlation between antigen expression and epitope presentation on MHC class I 
molecules, using the two delivery systems: Viral Replicon Particles (VRPs) and the synthetic 
Lipid Nanoparticles (LNPs). Moreover, we moved toward an in vivo model investigating the 
antigen expression in muscles and the draining lymph nodes at the site of injection. With this 
data we would improve the tracking of antigen following SAM vaccination, understanding the 
main differences between LNPs and VRPs mechanism that might involve cellular internalization, 
antigen expression or peptide presentation.  
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RESULTS AND DISCUSSION 
Part I 
3.1 Experimental strategies set up. 
 
3.1.1 Generation and characterization of Influenza replicon for proteomic studies 
 
SAM vectors encoding full-length Nucleoprotein (NP) gene from Influenza virus 
A/Puerto Rico/8/1934 (H1N1) pandemic strain was generated as a monocistronic SAM (NP) 
vector (Figure 7, A). The NP gene was amplified from the reverse-transcribed RNA genome of 
the virus, and then cloned into the DNA plasmid backbone containing the specific promoter for 
the T7 bacteriophage RNA polymerase [29]. The plasmid was transformed in Escherichia coli 
and purified by alkaline cell lysis and DNA anion exchange chromatography. Plasmid DNA was 
then linearized by PmeI endonuclease digestion using a unique restriction site downstream the 3’ 
end of transcription cassette and isolated by phenol/chloroform extraction and ethanol 
precipitation. Linear plasmid DNA was transcribed into RNA through the in vitro transcription 
reaction and purified by LiCl precipitation. Finally, to increase RNA stability, a poly (A) tail was 
added to RNA by enzymatic post transcription reaction and further purified by LiCl 
precipitation. The quality and the integrity of purified nucleic acids, both DNA and RNA were 
assessed by agarose gel electrophoresis: expected molecular weights and no products of 
degradation were observed (Figure 8, B). 
 
Fig. 8. Schematic representation of SAM (NP) generation  
(A) Schematic representation of SAM (NP) construct. SAM derived from alphavirus genome, contains a 
5’ cap, four nonstructural genes (nsp1-4), a 26S sub-genomic promoter (grey arrow), the vaccine gene 
antigen (NP in this study) and 3’ polyadenylated tail. (B) Analysis on agarose gel electrophoresis of the 
DNA or RNA obtained in each of four steps: circular amplicon, linearized DNA and RNA before and 
after the capping reaction.  
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The functionality of the replicons was evaluated by their self-amplification ability in Baby 
Hamster Kidney cells (BHK), a cell line usually used in molecular biology as a host for nucleic 
acid transfection. In details, BHK cells were transiently transfected through electroporation with 
an increasing amount (from 200 to 800 ng) of NP encoding mRNA. Amplification and antigen 
expression were evaluated by intracellular staining (ICS) and flow cytometry using two 
monoclonal antibodies selected for ds RNA and NP antigen (Figure 9).  
From this analysis the percentages of NP and dsRNA positive cells matched and were correlated 
to the RNA amount used, indicating the production of functional RNA with replication 
capability.  
 
Fig. 9. Characterization of SAM (NP) vector:  
NP vector was characterized analyzing RNA amplification capability by intracellular antigen expression 
after transfection in BHK cells with 200-400-600-800 ng of RNA. Thymus RNA and mock were used as 
negative control. The graph shows the percentage of cells containing replicating SAM vectors (dsRNA
+
) 
that correlates with the frequency of antigen expressing cells (NP antigen
+
).  
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3.1.2 Production and purification of Viral Replicon Particles (VRPs) encoding NP 
 
There are limited published data on the in vivo delivery of self-amplifying RNA using 
non-viral delivery strategies; instead there have been extensive works on the viral delivery of 
RNA molecules using Viral Replicon Particles (VRPs) that are potent vaccines in mice, non-
human primates and humans. These single-cycle alphavirus vectors are considered the most 
efficient tools to deliver nucleic acids into cells and for this reason, they were selected in this 
present study as nucleic acid delivery benchmark.  
VRPs were produced into a susceptible cell line usually, BHK cells, as previously described 
[62]. In this system, the NP expressing replicons were packaged into VRPs by co-electroporation 
in BHK cells along with defective helper RNAs encoding the Sindbis virus capsid and 
glycoprotein. In detail, capsid and envelope glycoproteins genes were amplified from the 
reverse-transcribed RNA genome of Sindbis virus and then cloned into DNA plasmid backbone 
under the transcriptional control of bacteriophage SP6 promoter. The plasmid was transformed in 
Escherichia coli and purified by cell alkaline lysis and anion exchange chromatography. Plasmid 
DNA was then linearized by PmeI endonuclease digestion and isolated by phenol/chloroform 
extraction and ethanol precipitation. Finally, to increase RNA stability, a poly (A) tail was added 
to RNA by enzymatic post-transcription reaction further purified by LiCl precipitation.  
At 24 and 48 hours post co-electroporation, VRPs (NP) were released to BHK media (Figure 
10). Finally, highly purified VRPs were obtained from the harvested supernatants through 
“sucrose cushion” by sucrose gradient zonal ultracentrifugation. 
 
Fig. 10. Schematic representation of VRPs production.  
VRPs were produced by co-electroporation of BHK cells with replicon RNA, encoding the NP gene, 
along with defecting helper replicon encoding glycoproteins and capsid genes. 
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Viral replicon particles titers were determined by intracellular staining of expressed NP protein 
antigen follow by an overnight infection of BHK cells with three serial dilutions of particles. By 
flow cytometry analysis, the percentage of positive NP cells was determine and used to calculate 
the titer. In previous work by Balsitis et al., calculation has been found to be consistently linear 
when cells are 2-60% positive post infection. In the table below, (Table 1) our result are 
summarized. The two dilutions allowed determining a titer of 5.7x10
8
 infection unit per ml.  
 
Table 1. Evaluation of VRPs titer (Infection unit per mL) by flow cytometry data.  
The calculation of VRPs titer was performed based on the percentage of positive cells to infection. The 
calculation has been found to be consistently linear when cells are 2-60% positive. 
  
Diluition factor % positive cells Infected cells VRPs Titer (IU/mL) Average (IU/mL)
250 43,2 3,22x105 4,03x108
1250 18,7 1,18x105 7,38x108
NP-VRPs 5,7x108
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3.1.3 Non-viral delivery system for SAM vaccines, Lipid Nano Particle 
(LNPs)/RNA formulation 
 
RNA molecules were encapsulated in a non-viral delivery system based on lipid 
nanoparticle as previously described [29]. 
Briefly, the lipids 1,2-Diasteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilinoleyloxy-N,N-
dimethyl-3-aminopropane (DLinDMA), Cholesterol, 1,2-dimyristoyl-sn-glycero-3-
phospethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (PEG DMG 2000) 
and cholesterol, were combined at molar ratio of 40:10:2:48 (DLinDMA:DSPC:PEG-DMG 
2000:cholesterol) by an ethanol dilution to produce the LNP (Figure 11) .  
 
Fig. 11. Schematic illustration of Lipid nanoparticle (LNP) structure. 
This system is composed of zwitterionic lipid, cationic lipid, cholesterol, and PEGylated lipid, formulated 
with self-amplifying mRNA (Adapted from Self-amplifying mRNA vaccines. Adv Genet, 2015) 
 
 
 
LNPs were produced mixing through a T-Junction, with a syringe pump system, equal volumes 
of lipid in ethanol and RNA in 100 mM citrate buffer at molar ratio 8:1 N:P (Nitrogen from 
DLinDMA: phosphate on RNA). The resulting LNPs were dialyzed overnight at 4°C against 
PBS and then characterized for particle size, RNA encapsulation efficiency and RNA integrity as 
previously described [29]. 
The formulated LNPs were characterized by dynamic light scattering (DLS) evaluating the mean 
particle size and polydispersity index. The Z-average diameters ranged from 160 to 170 nm with 
a low polydispersity index ranging from 0.09 to 0.14, indicating the formation of small and 
uniform lipid particles. The percentage of RNA entrapment was evaluated from the difference of 
“unencapsulated amount” of RNA measured before and after LNPs Triton treatment. The data 
showed that lipid particles are able to encapsulate more than 90% of mRNA (data not shown). 
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Moreover the RNA integrity was evaluated by agarose gel electrophoresis after RNA extraction 
from LNPs and comparison with NP-RNA prior the formulation in the LNPs (Figure 12). 
 
 
Fig. 12. Characterization of NP SAM-LNPs. 
(A) Size distribution of standard LNPs formulated with T-Junction were provided by DLS. The size 
distributions were characterized by a single peak with a low polydispersity index, indicating a relatively 
monodisperse size distribution. (B) Evaluation of NP-RNA integrity on agarose gel electrophoresis. 
Comparison between NP-RNA extracted from LNPs (line 1) and NP-RNA prior the formulation in the 
LNPs (line 2).  
  
A B
1 2
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3.1.4 Absolute quantification of Nucleoprotein antigen by Selected Reaction 
Monitoring (SRM) mass spectrometry 
 
With the purpose to specifically quantify the NP expression from a complex biological 
background, such as mammalian cell lysate, we employed Selected Reaction Monitoring (SRM), 
a quantitative mass spectrometry technique for the detection and quantification of specific, 
predetermined analytes with known fragmentation pattern [68]. 
In this assay, isotopically labeled peptides identical to those deriving from the tryptic digestion 
of the NP protein (proteotypic peptides, PTPs), were used as surrogates for the final protein 
quantification. 
In particular, we developed an experimental approach in which isotopically forms of PTPs of 
known amount were spiked in the biological sample before trypsin digestion to increase the 
accuracy of the antigen quantitation.  
 
3.1.4.1 Selection of proteotypic peptides (PTPs) for NP quantification 
 
The PTPs were experimentally selected from the tryptic digestion of commercially 
available recombinant form of Nucleoprotein and the generated peptides were analyzed by nano 
LC-MS/MS in an ESI-Q-TOF instrument in data dependent acquisition mode. The spectra 
obtained by MS/MS were processed using MASCOT search engine program against a database 
containing the Nucleoprotein protein sequence deduced from the pandemic strain A/Puerto 
Rico/8/34/H1N1 genome. This search provided a list of 29 peptides that covered the 56% of NP 
amino acid sequence (Table 2).  
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Table 2. NP peptides identified by LC-MS/MS analysis. 
List of 29 peptides obtained from the MS/MS spectra analysis by MASCOT program. In the table, 
peptide sequence, m/z value, Mascot Score and modified amino acids identified were reported.  
 
 
 
From this list, we selected five proteotypic peptide (PTPs) (highlighted in red) that do not 
displayed amino acids with observed and predicted chemical modifications (glutamine and 
asparagine deamidation, cysteine and methionine oxidation, N-terminal glutamine for 
cyclization), and present a specific length from 5 to 20 amino acids. Moreover peptides with low 
Mascot score and generated form of digestion site characterized by KK, RK, RR, KR 
consecutive amino acids, which lead of an incomplete tryptic digestion, were neither selected. 
Furthermore each PTPs were investigated for the uniquely association to the targeted protein in 
the specific biological background. For this reason the sequence of the selected PTPs were 
inspected against a database containing sequences deduced from the C3H mouse model genome 
and no matches were found. 
K.RSYEQMETDGER.Q 506,2178 32 Oxidation (M)
R.SYEQMETDGER.Q 673,2819 29 Deamidated (NQ) & Oxidation (M)
R.SYEQMETDGERQNATEIR.A 724,9937 72 Oxidation (M)
R.QNATEIR.A 417,2212 8 Deamidated (NQ)
K.MIGGIGR.F 360,1988 31 Oxidation (M)
K.LSDYEGR.L 420,2016 35
R.LIQNSLTIER.M 594,3436 72 Deamidated (NQ)
R.MVLSAFDER.R 542,2623 60 Oxidation (M)
K.YLEEHPSAGK.D 565,7797 54
K.KTGGPIYR.R 446,2588 10 KK-RR
K.TGGPIYR.R 382,2069 43 RR
R.QANNGDDATAGLTHMMIWHSNLNDATYQR.T 816,3634 46 Deamidated (NQ) & Oxidation (M) 
R.TGMDPR.M 338,6595 12 Low MASCOT score
K.GVGTMVMELVR.M 604,3273 56  Oxidation (M)
R.IAYER.M 326,1771 8 Low MASCOT score
K.AMMDQVR.E 441,7009 45 Oxidation (M)
R.NPGNAEFEDLTFLAR.S 847,9266 96 Deamidated (NQ)
R.SALILR.G 336,7262 37
R.EGYSLVGIDPFR.L 676,8499 100
R.LLQNSQVYSLIRPNENPAHK.S 774,4168 136
R.VLSFIK.G 353,7304 22 Low MASCOT score
R.GVQIASNENMETMESSTLELR.S 1170,5493 65 Deamidated (NQ)+ Oxidation (M)
R.YWAIR.T 354,6956 20
R.ASAGQISIQPTFSVQR.N + 846,4595 8 2 Deamidated (NQ)
R.NLPFDR.T 381,705 34 Deamidated (NQ)
R.TTIMAAFTGNTEGR.T 743,3476 3 Oxidation (M)
R.MMESARPEDVSFQGR.G 591,2666 60 Deamidated (NQ) & 2 Oxidation (M)
R.GVFELSDEK.A 512,2559 42
% NP coverage 
56%
Mascot ScorePeptide Observed (m/z) Key selection criteria
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PTPs were then investigated for the quality of MS/MS spectra in Q-TOF and triple quadruple 
instrument and the three of them that present the most intense fragment ions were finally selected 
(Figure 13). PTPs sequences are: SALILR (residues 262 to 267), EGYSLVGIDPFR (residues 
304 to 315) and GVFELSDEK (residues 472 to 480) located in the middle and N terminus of NP 
sequence.  
 
Fig. 13. MS/MS spectra of selected PTPs.  
MS/MS spectrum of the three most intense fragment ions associated to each selected PTPs In the right 
panel of the figure the specific PTPs properties are summarized: m/z of parent ions (Q1) and the selected 
fragment ions selected (Q3), charge state of the parental ion (z
+
), and the ion type of the three selected 
fragments . 
 
 
 
For these three peptides, SRM transitions were selected, representing the precursor ion mass and 
three different characteristic fragment ions required to reduce the possibility of false positives 
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during the analysis. This is particularly relevant for the analysis of complex mixture of peptides 
in which co-eluting isobaric peptides exhibiting similar primary structure.  
For an accurate quantification of NP in the biological sample, the stable isotope dilution method 
(SID) was selected. For this reason the identified PTPs were synthetized either in light- and 
heavy-labeled forms by incorporating 
13
C-
15
N lysine or arginine residues and quantified by the 
provider according to amino acid composition analysis (JPT Peptide Technologies GmbH). The 
peptides were used to build up a linearity curve, moreover the heavy-labeled one were also used 
as a spike of a known amount in the sample to precise protein quantitation. 
These synthetic peptides were also used to optimize another fundamental parameter in SRM 
transition, the collision energy (CE) value associated to fragmentation in the Q2 collision cell.  
In order to obtain the higher fragment ion signal intensities, collision energy (CE) optimization 
was performed in SRM acquisition in which panels of different CE were applied to the parental 
ions in order to monitor their fragmentation and the correspondently peak area.  
The optimized PTPs transitions for NP were reported in the Table 3, both for light and heavy 
labeled PTPs form. 
 
Table 3. List of optimized SRM transitions for the selected PTPs 
  
Q1 Q3 Q1 Q3 CE
Voltz
401,286 411,295 12
514,371 524,329 14
585,408 595,416 16
591,298 599,312 20
720,341 728,355 18
867,409 875,423 16
704,372 714,382 23
803,441 813,499 23
1003,55 1013,55 23
Light Heavy
m/z m/z
SALILR 336,724,  Z+= 2 341,728
GVFELSDEK 512,253, Z+= 2 516,261
EGYSLVGIDPFR 676,846, Z+= 2 681,85
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This approach was also used to determine the optimal SRM transitions for the detection of NP 
immunodominant peptide SDYEGRLI (H-2K
K
 haplotype). This peptide is well ionized and 
results in a MS good signal, moreover is not characterized by amino acids prone to chemical 
modification. For all this reason is considered as a good candidate for proteomic studies. 
Transitions were selected among the most intense fragment ions to maximize the sensitivity 
(Table 4). 
 
Table 4. List of optimized SRM transitions of the immunodominant MHC H-2K
k
 class I peptide. 
  
Q1 Q3 Q1 Q3 CE
Voltz
SDYEGRLI 476,74, Z+=2 458,307 480,24 465,324 23
587,35 594,367 23
750,413 757,432 23
Light Heavy
m/z m/z
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3.1.5 SISCAPA development method for low abundance protein quantitation in 
complex biological sample by SRM. 
 
In this study, SRM has been applied to protein quantitation in complex biological 
samples as cell lysate or tissue homogenates characterized by an extreme difference in the range 
of expression. In particular for low abundance expressed proteins, the decrease of sample 
complexity and the increase of targeted SRM assay sensitivity are required for the quantitation of 
those proteins. 
For this reason, here we have investigated an approach (summarized in Figure 14), that 
exploited the unparalleled ability of antibodies to specifically extract a target peptide in a 
complex biological matrix. This method termed Stable Isotope Standards and Capture by Anti-
Peptide Antibodies (SISCAPA) have been pioneered by Anderson in 2003 and combines 
quantitative MS up-stream to immune affinity enrichment of desired peptides in an immune 
SRM assay [62]. This approach was applied for NP antigen and MHC class I immune-dominant 
peptide quantitation. 
 
Fig. 14. Schematic diagram of the SISCAPA method for peptide quantitation  
SISCAPA approach combines four elements previously described: (1) digestion of a protein sample to 
peptides; (2) addition of internal standard peptides labeled with stable isotopes; (3) enrichment of low 
abundance peptides by capture with anti-peptides antibodies; and (4) quantitation by MS. (Adapted from: 
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins, 
Anderson, 2006). 
 
 
 
To obtain immune-dominant sera for the selected PTPs and NP-MHC I peptide, the synthetic 
form of the peptides were produced, conjugated to Bovine Serum Albumin (BSA) or Keyhole 
Limpet Hemocyanin (KLH) via N-terminal cysteine (JPT Peptide Technologies GmbH) and used 
to immunize rabbits. 
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In details, two New Zealand White rabbits (for each single peptide) were immunized, according 
to 49-day protocol of 3 injections, three and two weeks apart, with 50 μg of synthetic BSA 
conjugated peptides in alum adjuvant. 
To assess the presence of peptide specific IgG, sera from each rabbit were collected two weeks 
post third immunization and used to determine antibody titer by indirect ELISA, spotting KLH-
conjugated peptides onto microtiter plates. Rabbit sera with the higher titer were chosen as a 
source of polyclonal antiserum. ELISA titers obtained for MHC Peptide-BSA antibody were 
reported in Figure 15 as an example. 
  
Fig. 15. ELISA titers from sera derived from New Zealand White rabbits immunized with MHC-I 
peptide conjugated to BSA carrier. 
(A) Serum and pre-immune serum samples were 2-fold serially diluted in PBS containing 1% (w/v) BSA 
0.05% (v/v) Tween, and transferred into the coated and blocked plates. After 1 h incubation, plates were 
incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG to detect antigen-specific IgG 
antibodies. Absorbance was measured at 405 nm after addition of P-nitrophenyl phosphate disodium 
substrate. (B) The titers were normalized respect to the pre-immune serum assayed in parallel, choosing 
an OD threshold=1, and indicated as ELISA Units/ml (EU/ml). Rabbit number two, (in violet) shows 
antibody titers significantly higher than those obtained with rabbit number one (in green), for this, the 
corresponding serum was used as antibody source.  
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Antibodies were then purified by affinity on Protein G and eluted with glycine-HCl pH 2.5 
immediately followed by neutralization to pH 7.0 with Tris-HCl pH 8.0 to preserve antibody 
activity. IgG concentrations were spectrophotometrically determined evaluating sample 
absorbance (A) at 280 nm using the specific mass extinction coefficient (ε) established for most 
of mammalian antibodies. Antibodies purified from the affinity chromatography were checked 
by SDS-PAGE in reducing conditions. As an example, in Figure 16 (A), the electrophoresis 
profile of Ab generated for MHC class I peptide was reported. Dithiothreitol (DTT) reduces the 
disulfide bridges in the antibody molecule (~150 kDa), releasing light and heavy chains that 
appear as two distinct bands of 50 and 25 kDa. The protein profile on SDS-PAGE confirmed the 
purification of the Ab, with an average yield of 20 mg at a concentration of 1 mg/ml, starting 
from 20 ml of rabbit sera. 
Moreover the polyclonal antibody specificity was confirmed by dot blot assay Figure 16 (B) in 
which, KHL-conjugated peptides, BSA-conjugated peptides and BSA were spotted in the 
nitrocellulose membrane and revealed by anti BSA-conjugated peptides antibody. Figure 16 (B) 
shows that the purified antibodies present activity against BSA conjugated peptides and BSA 
alone. Selectivity towards peptides was evaluated identifying reactivity against KHL conjugated 
peptides. 
 
Fig. 16. Characterization of anti-peptide antibodies for SISCAPA method 
(A) The protein profile in reducing condition of SDS-PAGE stained with Coomassie Blue confirmed the 
purification of the Ab from individual rabbit 2. In red light and heavy Ab chain are highlight. (B) Dot blot 
assay confirmed the Ab specificity versus the specific peptides: purified Ab shows specificity not only 
versus BSA conjugated peptides and BSA but also against KHL conjugated peptide spotted in 
nitrocellulose membrane. 
  
H chain
(50 KDa)
L chain
(25 KDa)
A B
KHL 
conjugated
peptide
Anti BSA-conjugated peptide Ab
BSA
BSA 
conjugated
peptide
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Antibodies for all the selected PTPs were also produced and purified.  
ELISA titers, average amount and specificity for each antibody were summarized in Table 5  
 
 SALILR-Ab GVFELSDEK-Ab EGYSLVGIDPFR-Ab MHC I peptide-Ab 
Higher Elisa titer 1200 EU/mL 525 EU/mL 1500 EU/mL 989 RU/mL 
Average amount (mg) 25 14 32 20 
Specificity + + + + 
 
Table 5. List of antibodies produced and purified for all PTPs and immunodominant MHC class I 
peptide  
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Part II 
3.2 Characterization of NP expression during SAM vaccination: an 
in vitro model system. 
 
Preliminary data, suggested that muscle cells play an important role during in vivo SAM 
vaccination [24]. Many studies have shown that intramuscular injection of mRNA encoding 
reporter genes, results in protein expression in myocytes. Also for SAM vaccines, different 
studies have reported that antigen expression occurred mostly in the muscle fibers after RNA 
administration with a lipid-based delivery system. To better elucidate the in vivo antigen 
expression during SAM vaccination, we started to set up an in vitro cellular model using the 
myoblast cell line C2C12. 
In Figure 17 a schematic representation of myoblast cell line (C2C12) SAM transfection in a 
time course experiment is represented. Myoblast cells were collected at different time point after 
SAM transfection and intracellular Nucleoprotein expression was evaluated trough intracellular 
staining (ICS), flow cytometry and quantitative mass spectrometry assays.  
For the flow cytometry analysis, myoblast cells were intracellular-stained with a fluorescent 
isothiocyanate (FITC)-labeled anti NP antibody in order to identify the percentage of NP positive 
cell. On the other hand, NP absolute quantification in total cell lysate was performed by SRM. 
The results obtained from both techniques allowed measuring the NP molecule number per 
myoblast cell that we defined as “NP cellular abundance”.  
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Fig. 17. Schematic workflow of experimental strategy. 
Cell line C2C12 was transfected by SAM, and at different time point after transfection cells were 
collected and counted. NP expression was analyzed using flow cytometry and its absolute abundance in 
total cell lysate was performed by quantitative mass spectrometry. 
 
 
 
3.2.1 Characterization of protein antigen expression in myoblast cells, comparing 
VRPs infection and SAM transfection.  
 
In order to define the experimental model employed in the characterization of protein 
antigen expression upon SAM vaccination, cell line C2C12, were treated with NP expressing 
Viral Replicon Particles NP-(VRPs), taking advantage of their high in vitro infection rate. The 
same approach was then applied to SAM, in which myoblast cells were transfected with LNPs.  
In details, C2C12 were treated with two different NP-(VRPs) and NP-(LNPs) amounts to 
monitor protein antigen expression during 24 hours by ICS and SRM.  
Two amount of VRPs (10
5 
and 10
6
 Infection Unit (IU) were used to infect 200.000 C2C12 cells, 
grown at confluence. At 2, 4, 12, and 24 hours, the cells were collected and the percentage of NP 
positive cells were assesses by ICS and flow cytometry. The results were summarized in Figure 
18. For both amount of VRPs an early antigen expression was observed already at 2 hours post 
infection (hip). With the lower amount (10
5 
U.I., in blue in the graph represented in Figure 11) a 
maximum of positive cells, corresponding to 60% of the total cells were observed at 4 and 12 
hours, at 24 hours NP positive cells was 30%. The diminution of NP positive cells between 12 
and 24 hours might reflect the intracellular degradation or loss of functionality of the dsRNA or 
NP protein. The integrity of the cells at this time point was checked by flow cytometry to 
Quantitative MS analysis
C2C12
Time lapse experiment
Flow cytometryCell counting
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exclude potential cellular lysis. This behavior was not observed for the infection with the higher 
amount of VRPs (10
6 
U.I., in red in the graph represented in Figure 18) where almost all 
myoblast cells were positive to NP expression at all time point, probably reflecting a high 
amount of dsRNA uptake per cell. 
 
 
Fig. 18. Intracellular staining and flow cytometry assay to identify the positive percentage of myoblast 
cells to NP expression during VRPs infection. 
Cell line C2C12 was infected with 10
6
 VRPs IU (in red) and 10
5
 VRPs IU (in blue) and the NP 
antigen expression were monitoring during 24 hours post infection by ICS and flow cytometry using a NP 
antibody FITC conjugated. Histograms represent the percentage of NP 
+
 myoblast. Data are representative 
of three independent experiments.  
 
 
 
No quantitative information could be obtained from this type of analysis. For this reason SRM 
was applied in parallel to determine the absolute quantitation of NP protein antigen. With this 
purpose, myoblasts cells from each time point, were lysated and subjected to reduction and 
alkylation. The labeled form of three PTPs were then added and the mixture were subjected to 
trypsin digestion using the FASP (filter assisted sample preparation) method previously 
described [81] and detailed in the material and methods section in order to quantify the endogen 
PTPs as surrogate of NP quantitation.  
The amount of endogen PTPs was deduced from a calibration curve established in a matrix that 
mimics the same “environment” of the sample. To build this curve, a fixed amount of heavy 
forms of PTPs (25 fmol/µg of 
13
C-
15
N-labeled PTPs) and scalar concentration of light PTPs 
(ranging from 0,2 to 810 fmol/µl) were added to a fix amount of matrix (1 μg of C2C12 total cell 
lysate). The protein and peptide mixture was digested with trypsin and the peptides were 
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analyzed by LC-SRM. Each PTPs concentration was plotted against the light and heavy peak 
area ratio obtained in order to account any variations during LC-MS approach as loading sample 
step, age of column, perturbations during the LC run etc.).  
As an example, the dose range-response curve of the PTP GVFELSDEK is reported in Figure 
19. The response was linear from 1,6 to 405 fmol/µl and the Lower Limit of Quantitation 
(LLOQ), defined as the lowest concentration point on the fitted curve with an accuracy deviation 
≤ 20%, was established at 3.2 fmol/µl. Considering an average molecular weight of 56,000 Da 
for NP molecule, a low limit of quantification of 0.6 pg per 1 µg of total cell lysate was 
calculated. 
 
 
Fig. 19. Dose-response curve of PTP GVFELSDEK. 
 
 
 
The lower limit of quantification was simultaneously identified for all PTPs and, the highest 
value obtained, was used to define the global NP LLOQ. In this case, the value achieved for all 
PTPs was the same, (0,6 pg per 1 μg of total cell lysate), and was used as standard to the further 
quantifications.  
Moreover to evaluate the interchangeability of three PTPs selected for the analysis; NP protein 
antigen quantification was performed in each considered time point. The coefficient of variation 
(% CV) at each PTPs, ranged from 10 to 15%, showing a low overall data variability and 
indicating the interchangeability of all PTPs (data not shown).  
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In Figure 20 the simultaneous PTPs signal detection for both, light and heavy form, performing 
during LC-SRM approach was shown. 
 
 
 
Fig. 20. Simultaneous detection of multiple PTPs by LC-SRM MS.  
Multiplexed detection of 3 PTPs. A mixture of each synthetic light and heavy peptide, 800 fmol and 50 
fmol respectively, were loaded and analyzed directly by LC-SRM using a method to detect all peptides 
simultaneously. The mass chromatogram represents mass spectrometry data, where the x-axis represents 
the time of analysis and the y-axis the signal intensity. Line 1 defines the mass chromatogram derived 
from the total ion current (TIC) that represents the summed signal intensity across the entire range of the 
selected masses detected at every point in the analysis. In the other lines, the mass chromatogram derived 
only from signal intensity associated to each PTPs. Co-elution of light and heavy peptide was observed 
between line two-three for SALILR peptide, line four-five for GVFELSDEK peptide and line six-seven 
for EGYSLVGIPFR peptide.  
  
SALILR
GVFELSDEK
EGYSLVGIPFR
Light : 336,724 m/z
Heavy : 341,728 m/z
Light : 512,253 m/z
Heavy : 516,261 m/z
Light : 676,846 m/z
Heavy : 681,85 m/z
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2
3
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5
6
7
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Precise quantitation of NP protein antigen from each time point was measured. NP protein 
antigen was already detected and quantified at two hours post infection. For the both doses, no 
increase of NP amount was observed until 4 hours, followed by a substantial increase of 
expression, peaking around 12 hours post infection. Steady amount was observed until 24 hours 
post infection (Figure 21).  
 
 
Fig. 21. Absolute quantification NP protein in 1 µg of total cell lysate over the course of VRPs 
infection.  
The red line represents the NP quantitation during the infection with 10
6
 VRPs IU instead the blue one 
represents the NP quantitation after infection with 10
5
 VRPs IU. In green the negative control in which 
cell are infected by empty VRPs. 
 
 
 
The early antigen detection and quantitation evaluated with VRPs probably reflecting the high in 
vitro infection capability of alphavirus particle. The time frame required to protein detection in 
our experiment (2 hours) is consistent with previously published data that have reported how 
alphavirus infection process occurs. In fact, only when an appropriate interaction between virus 
and cellular receptors is established, the process of transferring virus genome to the cell interior, 
mediated by E1 an E2 glycoprotein, can take place allowing the detection of specific RNA virus 
and proteins. All these events, during alphavirus infection occur in a time frame of 1-2 hours as 
we observed in our experiment. 
Moreover, from results obtained by ICS and SRM, the copies of NP antigen per myoblast cell 
were estimated (NP cellular abundance) (Figure 22). 
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From this data, an increase of NP protein antigen copies per cells between 4 to 12 hours post 
infection was observed for both VRPs IU. In particular, for 10
5
 VRPs IU, the NP cellular 
abundance increases from around 4x10
5
 to 9x10
6
, reaching 1.5x10
7
 molecules at 24 hours post 
infection. For 10
6
 VRPs IU, NP protein abundance increases from 7x10
5
 to 8x10
6
, reaching 
around at 1x10
7
 molecules at 24 hours post infection. From this results we can observe that the 
NP cellular abundance at 24 hours post infection, obtained from 10
6 
VRPs IU is about a third of 
that observed with 10
5
 VRPs IU. 
 
 
Fig. 22. Absolute quantification of NP protein in myoblast cell over the course of VRPs infection. 
Histograms represent NP abundance in myoblast cell for each time point. In blue value for 10
6
 VRPs IU 
was represented instead the red one where the value for 10
5
 VRPs IU.  
 
 
 
This is might be related to a toxic effect associated to high cellular level of NP encoding RNA. 
The intracellular production of high amount of ds RNA might induce the cellular RNA sensitive 
machinery that built a first barrier of defense against for example infection, inducing RNA 
degradation. On the other hand high RNA amount could be interfering with protein antigen 
expression, synthetizing truncated form of proteins which will degraded subsequently. Other 
possibilities could be considered and could be interesting to understand all biological processes 
such a signaling pathway, gene expression, protein-protein interaction and changes induced by 
this kind of environmental stimuli. SRM also in this case could be used as a key tool, having the 
capability to delve deep in a cellular proteome with high sensitivity and selectivity.  
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The same strategy was then applied to monitor NP protein antigen quantitation after in vitro 
SAM transfection using two different mRNA amounts: 250 ng and 2 μg. The percentage of NP 
positive cells was evaluated by ICS at 4, 12 and 24 hours post transfection (Figure 23) 
In this case the expression was observed at 12 hours post transfection. Moreover an increase of 
the percentage of NP positive cells from 3 to 8% was measured with 250 ng of RNA (in red) 
between 12 to 24 hours post treatment. This was not observed with 2 μg of RNA (in blue), where 
the NP positive percentage remain almost the same during the two time points.  
 
 
 
Fig. 23. Intracellular staining and flow cytometry assay to identify the percentage of myoblast cells that 
express NP protein antigen during SAM transfection.  
Cell line C2C12 was transfected with 2 μg (in blue) and 250 ng (in red) amount of LNP-SAM. NP 
antigen expression were monitoring during 24 hours by intracellular staining using. Histograms represent 
the percentage of NP 
+
 myoblast. Data are representative multiple experiment. 
 
 
 
Compering LNPs with VRPs a lower percentage of NP expressing cells was notice. This 
observation could be explain by low efficiency of LNPs internalization, release of RNA in the 
cells or moreover for low antigen expression. Quantitative approach was the applied to better 
elucidate this point. With this kind of analysis we were able to investigate only the NP antigen 
expression, without acquire more information related to LNPs internalization or the following 
RNA release.  
We then focused in the quantitative data, obtained by SRM, using the three PTPs as surrogates of 
protein quantitation (Figure 24) 
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NP protein antigen was detected and quantified only at 12 hours post transfection, consistent 
with what already seen by ICS. Moreover, for 250 ng of mRNA dose (in red), the NP amount 
substantial increase from 12 to 24 hours post transfection peaking around 35 fmol per 1 μg of 
total cell lysate. Different behavior was observed with 2 μg of mRNA for which constant low 
level of expression was observed. 
 
Fig. 24 Absolute quantification NP protein in 1 μg of total cell lysate during SAM immunization.  
The red line represents the NP quantitation with 250 ng of LNPs SAM, instead the blue one that represent 
the NP quantitation with 2 μg of LNPs SAM. In green the negative control in witch cell were not 
transfected. Value at 4 hours post transfection could not be monitored because < of LLOQ of analysis.  
 
 
 
From this data we can suppose that the lower percentage of NP expressing cells towards what 
observed with VRPs could be related to an inefficient LNPs transfection or RNA release. This is 
might be associated with the mechanism by which LNPs are internalized in the cellular system 
not mediated by receptors but probability due to electrostatic interaction between liposome, that 
hold a positive charge conferred by cationic lipid, and plasma membrane. Moreover low 
transfection efficiency could be also caused by a PEG-mediate liposome aggregation, not 
observed after formulation, but which could preventing desirable cell internalization. This 
phenomenon was amplified with 2 μg RNA dose, where a probable toxic effect due to high 
amount liposome affected the cell viability. 
These results were converted, as done for VRPs, to the number of NP copies per myoblast cell as 
shown in Figure 25. 
<LLOQ
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With 250 ng of mRNA dose, an increase of NP cellular abundance between 12 to 24 hours post 
transfection was observed from around 5x10
6
 to 4.5 x10
7
. Otherwise with 2 μg RNA dose, we 
did not appreciate the same trend, where no NP increase abundance was observed (3x10
6
 to 
3.7x10
6 
at 24 hours post transfection). 
 
 
Fig. 25. Absolute quantification of NP protein in myoblast cell after SAM transfection. 
Histograms represent NP abundance in myoblast cell for each time point. In blue values for 2 μg LNP 
SAM were represented, in red one where the values for 250 ng LNP SAM. 
 
 
 
To conclude, a different kinetic of NP protein antigen expression from VRPs and LNPs can be 
observed. In particular, with VRPs, NP was detected and quantified at 2 hours post infection. 
Otherwise, with LNPs, a different temporal expression was observed where the evaluation of 
protein amount could be performed at 12 hours post transfection. After detection, no evident 
differences in the intracellular amount of NP protein antigen were observed. With the 
experimental evidence that once internalized the step of antigen expression are in the same 
extent, we can assume that main difference between VRPs and LNPs is related to the mechanism 
of cellular uptake.  
  
 53 
 
3.3 Characterization of NP endogenous processing and MHC class I 
peptide presentation in myoblast cells during SAM transfection. 
 
To correlate the intracellular NP protein antigen expression with the subsequent antigen 
endogenous processing on MHC complex system, SRM was employed to perform the absolute 
quantitation of MHC class I associated peptide at different time point after SAM transfection. 
Myoblast cell line C2C12 and VRPs represented a suitable in vitro tool to validate the 
experimental set-up, in order to characterize the NP protein antigen presentation on MHC class I 
system upon SAM vaccination.  
In detail, 5×10
8
 C2C12 cells were treated with NP-(VRPs) or NP-(LNPs), harvested at different 
time points and lysated in order to monitor peptide epitope presentation. MHC K
k
-peptide 
complexes from lysed cells were captured by immunoaffinity chromatography using a 
monoclonal anti MHC H-2K
k 
haplotype antibody bound to protein G-Sepharose. Bound MHC-
peptide complexes were dissociated and eluted with 10% acetic acid. Peptides were separated 
from MHC class I heavy chain β2m and polymers from detergent by filtration through a low 
protein binding spin filter and then subjected to LC-SRM analysis. The use of immunoaffinity 
chromatography drastically improves the specificity of the peptide extraction process and 
provides the most appropriate material to identify individual peptide ligand restricted by a 
defined MHC allele.  
 
Fig. 26. Representation of approach used to study antigen presentation using mass spectrometry. 
In this protocol, cells were treated with VRPs or LNPs. At various time points, cells were harvested and 
lysated. Mass spectrometry analysis employed the targeted method of LC-SRM, where the known MHC-I 
peptide is detected and quantified. (Adapted from Kinetics of antigen expression and epitope presentation 
during virus infection. PLoS Pathog, 2013) 
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During immunological response, CD8
+
 T cell are often skewed toward a small number of 
peptides in a phenomenon known as immune-dominance. For this reason, the immunodominant 
peptide SDYEGRLI predicted and identified as K
k
-restricted epitope in Influenza virus 
Nucleoprotein (residues 50 to 63) [82] was selected to quantitation and synthetized either in 
light- and heavy-labeled forms by incorporating 
13
C-
15
N in the isoleucine residue and quantified 
by the provider according to amino acid composition analysis (JPT Peptide Technologies 
GmbH).  
To obtain an accurate peptide epitope quantitation the internal standard dilution (ISD) approach 
was employed and a known amount of stable isotope-labeled version of the immunodominant 
peptide was spiked into the sample. This heavy labeled peptide was added prior the filtration step 
to account for losses during sample preparation. The amount of immunodominant peptide was 
deduced from a calibration curve established in a matrix that mimics the same “environment” of 
the sample to be analyzed the same amount of no treated myoblast cells immunopurified for 
cellular MHC complex. To build this curve, a fixed amount of heavy forms of PTPs (25 fmol/µg 
of 
13
C-
15
N-labeled PTPs) and scalar concentration of light PTPs (ranging from 0.2 to 810 
fmol/µl) were added to a fix amount of matrix. After LC-SRM assay, SDYEGRLI peptide light 
and heavy peak area ratio obtained was plotted against concentration. In Figure 27 calibration 
curve was reported. The response was linear from 1.6 to 405 fmol/µl and the Lower Limit of 
Quantitation (LLOQ), was established at 1.6 fmol/µl. Considering an average molecular weight 
of 952 Da, a low limit of quantification of 0.6 pg per 1 µg of total cell lysate was calculated and 
used for further quantification.  
 
Fig. 27. Dose-response curve of SDYEGRLI immunodominant H-2K
K 
peptide.  
For this PTP the LLOQ is 1.68 fmol/μl.  
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Absolute quantitation of SDYEGRLI peptide was performed after VRPs infection of 5×10
8 cells 
at 6 and 24 hours post infection.  
The two selected time points were chosen to discriminate the specific phases that describe NP 
antigen expression after VRPs infection (Figure 28). In particular, 6 hours matched with the 
phase of antigen expression instead to 24 hours that corresponded to last antigen measured 
amount. 
Peptide SDYEGRLI was already detected and quantified already at six hours post infection 
reaching around 27 pg per 5×10
8 cells and then decreasing until 2 pg (<LLOQ) at 24 hours post 
infection, from this study is clear that epitope presentation is essentially coincident with neo-
synthesis of the source protein antigen. Moreover, even if the source of proteins continued 
slowly rise after this time point, epitope turnover is rapid and not more detectable in the last time 
point. The number of copies of peptide SDYEGRLI per myoblast cell was estimated, 
SDYEGRLI presentation on C2C12 infected cells was calculated to be 343 copies per cell at 6 
hours post infection and 20 at 24 hours post infection (Figure 28).  
 
Fig. 28. Kinetic of NP antigen presentation after VRPs infection.  
C2C12 cell were infected with VRPs (or mock treated at time 0) and incubated for 6 and 24 hours. MHC 
peptides were eluted at each time point and epitope level monitored by LC-SRM. Data shows fmol of 
peptide in 5x10
8
 cells and the peptide copies of per cell, obtained considering the positive percentage of 
NP expressing cells (data representative of two independent experiments). 
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The same strategy was applied to evaluate the SDYEGRLI quantitation after in vitro SAM 
transfection of 5×10
8 
myoblast cells. 
The absolute amount was evaluated at 18 and 24 hours post transfection, where 18 hours 
matched with the phase of antigen expression instead to 24 hours that corresponded to last 
antigen measured amount. 
In this case the low positive percentage of NP expressing cells after SAM transfection did not 
allow us to detect and quantify SDYEGRLI. For this reason a SISCAPA approach was applied in 
order to decrease sample complexity and increase assay sensitivity by the immune affinity 
enrichment of this peptide MHC K
k
-peptide complexes were purified from lysed cells as 
previously described and the eluted peptides were further enriched by α-peptide antibody 
obtained from the development of SISCAPA method (detailed in the part one of the result 
section)The SDYEGRLI peptide, processed at NP protein, was detected and quantified at 18 
hours post transfection around 17 pg in of 5×10
8
 myoblast cells, tracked closely with the phase 
of protein antigen expression. A rapid decline in epitope levels at 24 hours post transfection was 
observed reaching a level below the limit of detection of the developed method. The copies of 
SDYEGRLI peptide for each myoblast cell was calculated to be 438 copies per cell at 18 hours 
post transfection and no more detectable at 24 hours post transfection Figure 29.  
 
Fig. 29. Kinetic on NP antigen presentation after LNPs transfection. 
C2C12 cell were transfected with LNPs (or mock treated at time 0) and incubated for 18 and 24 hours. 
MHC peptides were eluted at each time point and epitope level monitored by LC-SRM. Data show fmol 
of peptide in 5x10
8
 cells and the peptide copies of per cell, obtained considering the positive percentage 
of NP expressing cells. (Data representative of two independent experiments). 
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To conclude from our result we can observe for both delivery, a lag between peak of protein 
expression and peak of epitope presentation. In fact from this study is clear that, after NP-VRPs 
infection and NP-LNPs transfection, the epitope presentation is essentially coincident with neo-
synthesis of the source protein.  
Moreover, even if the source of proteins continues to slowly rise after the last time point, epitope 
turnover is rapid and then not more detectable after 24 hours post infection: the abundance of 
epitope varies massively from high of 400 to low of 20 copies per cells. All these results are 
consistent with previously published data [51], where the kinetic of multiple Vaccinia virus 
peptide epitope, and the corresponding viral protein were monitored by SRM. In that work, 
immunodominant peptide epitope, displayed on surface of antigen presenting cells, was 
characterized by a similar behavior, providing a strong support that antigen presentation is 
largely linked to translation and not later degradations of the antigens. Otherwise the epitope 
abundance measured in our experiment is tenfold lower than thus observed in this paper. In fact, 
even if muscle cells can acts as APC in the immune system, they do not express the CD80-CD86 
costimulatory molecules, needed for efficient presentation.  
Moreover, a high dynamic process characterized by multiple epitope simultaneously detected by 
SRM was described in the same paper. This lead to suppose that SAM presentation could not be 
described by only peptides and future works will focus to get more insight on peptide 
presentation during SAM vaccination. 
Obtained results, relating to NP protein antigen expression and subsequent intracellular 
endogenous processing on MHC class I molecules in myoblast cells line by VRPs or LNPs were 
summarized in the Table 6.  
 
Table 6. Kinetic of antigen expression and epitope presentation in in vitro model system with VRPs and 
LNPs.  
Comparison between the number of NP copies (in blue) and peptide epitope presented (in red) between 
the two delivery systems.  
  
2 hours 4 hours 6 hours 12 hours 24 hours 4hours 12 hours 18 hours 24 hours
438 Not-detected
LNPs infectionVRPs infection (105 VRPs IU)
<LLOQ 3,29 E6 3,70 E7
Number of copies for myoblast cell
MHC class I peptide 343 20
NP protein antigen 3,80 E5 4,13 E5 9,69 E6 1,42 E7
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A different kinetic of NP protein antigen expression between VRPs and LNPs can be observed. 
In particular, with VRPs, NP was detected and quantified already at 2 hours post infection, while 
with LNPs, a different kinetic of expression was observed, in which  the detection of protein 
amount happened only at 12 hours post transfection. After detection, no evident differences in 
the intracellular amount of NP protein antigen and in the level of epitope peptide bound on MHC 
class I molecules were observed.  
From this data we can assume that the main difference between VRPs and LNPs is related to the 
mechanism of cellular uptake: once RNA was internalized, the steps of antigen expression and 
peptide presentation are comparable. 
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3.4 Characterization of NP expression in mouse muscles and lymph 
nodes during SAM immunization.  
 
To better elucidate the antigen expression step upon SAM vaccination, an in vivo model 
system based on NP expressing antigen was employed. In particular, this model allowed 
investigating antigen expression and following epitope presentation in muscles and draining 
lymph nodes at the site of injection.  
Previous studies [24, 29] have been focused on the analysis of SAM vaccine-encoding antigen 
expression and localization, in an in vivo model based on reporter genes as firefly luciferase or 
secreted alkaline phosphatase (SEAP), where bioluminescence or chemioluminescence were the 
monitored outputs. With these assays a strong signal induced by LNP/RNA were observed, 
compared to those obtained from VRPs, that peaks at 7 days and persist for long time, until 49 
days after SAM immunization. These kinds of assays do not allow obtaining precise quantitative 
information insight the kinetics of protein expression. To overcome these limitations, SRM 
approach was used in this study. To correlate the in vitro result obtained with C2C12 cell line 
with in vivo conditions we used C3H mice as animal model system. This mice present the same 
H2-K
k
 haplotype of myoblast cell line C2C12, allowing to use the specific immunodominant 
epitope peptide SDYEGRLI for the further in vivo studies on MHC class I presentation. 
C3H mice were intramuscular (i.m.) immunized with 0.1 μg of SAM expressing NP delivered by 
LNPs, using PBS treated mice as negative control. Muscles at the site of injection and draining 
lymph node were collected after 6 hours, and one, three, eight and ten days after immunization 
and subjected to SRM analysis to evaluate NP protein antigen expression (Figure 30). 
 
Fig. 30. Schematic representation of immunological scheme for SAM in vivo study. 
C3H mice (n=25) were immunized i.m. with 0.1 µg of SAM (NP), five of them with PBS as negative 
control. Six hours, one, three, eight and ten days after immunization, 5 mice per group were sacrificed, 
and muscles and distal lymph node, at the side of immunization were collected to evaluate antigen 
expression at the selected time points.  
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In details, after collection, tissues were disrupted by mechanical homogenization. From tissue 
lysated, protein content were isolated by 2,2,2-trichloroacetic acid (TCA) precipitation and 
subjected to reduction, alkylation and tryptic digestion in order to obtain tissue peptide mixture 
to be analyzed by SRM for NP precise quantitation. For each time points, the three PTPs already 
used for the in vitro quantification, were monitored in a matrix that mimic the same complex 
“environment” that characterized muscle samples. This matrix was also used to create calibration 
curve to identify the linearity correlation between PTPs dose range and the MS signal obtained. 
As an example, the dose-response curve of the PTP GVFELSDEK in mouse muscle matrix was 
reported in Figure 31. The LLOQ was calculated as 89 pg for 1 μg of total tissue lysate. The 
same LLOQ was assessed for the two other PTPs and used as a standard value for NP protein 
antigen quantitation. 
 
Fig. 31. Dose-response curve of the PTP GVFELSDEK in mouse muscle. 
For this PTP the LLOQ is calculated at 1.6 fmol/μl. Considering an average NP molecular weight of 
56000 Da, the limit of quantitation is determined as 89 pg per 1 µg of total cell lysate. 
 
 
 
The abundance of NP protein antigen was precisely quantified on the treated total muscle, for 
each time points, in presence of a known amount of heavy spike as internal standard. 
Quantification was first performed evaluating the NP protein antigen amount in 1 μg of protein 
tissue lysate (data not shown). These values were then extrapolated to the total mass of mouse 
muscle tissue. Results are reported in Figure 32. 
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With 0.1 μg of SAM-LNPs dose used in the immunization, 25 ng of NP protein antigen was 
detected at 6 hours post immunization, no increase was observed until 8 post immunization 
where the amount was around 56 ng. The amount at 10 days post immunization was around 65 
ng. 
These results are consistent with published data obtained by luciferase report antigen in which 
peak of expression was monitored at 7 days post immunization. Further analysis should be 
performed to evaluate the persistency of NP protein antigen in mouse muscle. 
 
 
 
Fig. 32. Absolute quantitation of NP antigen during SAM immunization in total mouse tissue lysate.  
The absolute quantification of NP antigen expressed as ng per muscle, was performed at 6 hours (red), 1 
day (green) 3 days (black) 8 days (orange) and 10  days after immunization (magenta).  
 
 
 
To compare the results obtained in vivo with the dynamic range of the muscle proteome the NP 
amount measured at 10 days after immunization were compared to the amount of specific 
housekeeping proteins derived from the same muscle. To perform this kind of analysis, mouse 
muscle homogenate was digested with trypsin and the obtained peptides were measured using 
MS
E
 analysis in a data-independent acquisition mode. With this approach all detectable peptide 
ions were measured, without a priori knowledge of them. Quantification of proteins was 
performed spiking 200 fmol of internal peptide standard (rabbit phosphorylase b) into the 
sample. Thanks to the observation that the intensity of the three most intense (most efficiently 
ionized) tryptic peptides are linked to the protein amount, whatever the dynamic range of the 
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protein (Hi3 method), the amount of all proteins can be inferred by known amount of added 
standard (Figure 32) [83].  
 
 
Fig. 33. Schematic representation of the workflow used for sample preparation for total muscle 
proteins quantitation. 
Total muscle protein content were isolated through TCA precipitation and subjected to tryptic digestion. 
Rabbit Phos B was spiked in the peptides mixture as internal standard and analyzed by nano LC-MS
E
. 
Relative quantitation was performed comparing the three most intense peptide ions of the reference with 
the those obtained from each detected components. 
 
 
 
The obtained results were summarized in Table 7. 
Motor proteins, such as myosin, actin, troponin and tropomyosin represent the most abundant 
proteins in total muscle proteome.  
In particular, combining the abundance of all identified heavy and light myosin isoforms, they 
represent the 21% of total mouse muscle weight, positioning myosin as the highest abundance 
protein in skeletal muscle. In the same way, according to MS measurement, other high abundant 
proteins were alpha actin, troponin and tropomyosin that constitute the 3%, 4%, 0.2% and 0.17 
% of total mouse muscle respectively. Moreover, also protein involved in the skeletal muscle 
metabolism as glycogen phosphorylase (Pyg) constitutes the 0.5% of total mass muscle. This 
data are in accordance with the skeletal muscle proteome quantification recently published by 
Deshmukh et al [84]. NP protein expressed after SAM LNP infection represented the 0.0029‰ 
of mouse muscle proteome. Table 7 summarized these results.  
  
measured protein samples
tryptic digest
Spike in of digested reference
protein
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Table 7. MS quantification by label-free Hi3 method of the most abundant housekeeping proteins in 
mouse muscle tissue. 
Final protein amounts were calculated and expressed as mg per muscle and as percentage of the total 
mass muscle proteins.  
 
 
 
Moreover, the same approach was used to detect and quantify NP protein antigen in mouse distal 
lymph node at different time points after immunization. 
This information could be particular relevant in the vaccinology field since the lymph node organ 
promotes the interaction between T lymphocytes, B lymphocytes, APCs acquiring an important 
role rising both humoral and cell-mediated immune response.  
Within this purpose, LC-SRM assay was performed as described above starting prom the 
proteome of the distal lymph node. A new dose-response curve for NP PTPs were evaluated 
using lymph node proteome as matrix and the LLOQ for all PTPs was measured as 30 pg for 1 
μg of total lymph node lysate.  As an example, the dose-response curve of PTP GVFELSDEK in 
was reported in Figure 34. 
 
Fig. 34. Dose-response curve of PTP GVFELSDEK in lymph node. 
For this PTP the LLOQ was set at 0.6 fmol/μl. Considering an average NP molecular weight of 56000 Da, 
the limit of quantitation is determined as 30 pg per 1 µg of total cell lysate derived from lymph node. 
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Then the abundance of NP protein antigen was assessed on the treated total lymph node, for each 
time points, in presence of a known amount of heavy spike as internal standard.  
For each time point we detected a specific signal of NP but below the LLOQ for this experiment 
(30 pg per 1 µg of total cell lysate), and for this reason not quantifiable. This is a promising 
preliminary data and SISCAPA approach employed to overcome this limitation in sensitivity. 
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3.5 BM-DCs are not directly transfected by SAM encoding NP in in 
vitro model system. 
 
Previous studies have demonstrated that the in vivo priming of MHC class I restricted 
CD8
+
 T cells follow SAM vaccination involved Bone Marrow derived professional APCs, but to 
date no evidence of in vivo or in vitro direct transfection, evaluated by ICS and flow cytometry 
assay, was observed [80].  
From these observations we cannot exclude that some APCs can be transfected by SAM but 
express antigen at low level not detectable by any high sensitivity approach. To address this 
question, SISCAPA method was applied to increase assay sensitivity and allow detecting low 
amount of antigen expressed in transfected bone marrow-dendritic cells (BM-DCs) by SRM. 
SAM-expressing NP antigen was used as tool for our proteomic studies. 
In order to investigate if APCs can be transfected by a SAM vector and express the encoded 
protein antigen, an in vitro model system based on BM-DCs was set up. In detail 14 x 10
7
 BM-
DCs were transfected with SAM (NP/LNP) and harvested and lysate after 18 hours. Lysate was 
subjected to reduction, alkylation and trypsin digestion using the FASP method in order to obtain 
a tryptic cellular peptide mixture to be analyzed by SRM for NP precise quantitation. Previously, 
the immune affinity enrichment of PTPs was performed, using the specific anti-PTP m-Ab 
previously produced, in order to improve the sensitivity of the assay.  
The PTPs signals were monitored in a matrix that mimic the same “environment” that 
characterized immune-affinity enriched PTPs sample and the calibration curve useful to identify 
the linearity correlation between PTPs dose range and the MS signal was created. Each point of 
this curve was measured in a fixed amount of matrix (BM-DCs lysate immunoaffinity purified 
with anti-PTPs m-Ab) heavy form of PTPs and scalar concentration of light form (ranging from 
0.05 to 51 fmol/µl).  
The protein mixture was digested with trypsin, immune-affinity purified using αPTPs m-Ab and 
analyzed by LC-SRM. For each PTP, concentration was plotted against the peak area ratio 
(/Light/Heavy) obtained. As an example the dose-response curve of PTP GVFELSDEK was 
reported in Figure 35. During this step the LLOQ for all PTPs was set as 44 pg for 1 μg of total 
BM-DC lysate.  
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Fig. 35. Dose-response curve of PTP GVFELSDEK in BM-DC.  
For this PTP the LLOQ is detected at 0.6 fmol/μl. Considering an average NP molecular weight of 56000 
Da, the limit of quantitation is determined as 44 pg per 1 µg of total cell lysate. 
 
 
 
Two different analytical sessions were performed starting from two independent biological 
experiments. No detection of NP was measured in both experiments, suggesting that BM-DCs 
could not be transfected. 
Moreover, this data further indicate that APCs do not directly transfected by SAM. 
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3.6 BM-DCs are not directly transfected by SAM but can migrate 
toward transfected myoblasts in vitro model and take up exogenous 
NP expressed antigen. 
 
Previous studies evidenced that the direct expression of antigen in BM-DCs was not 
necessary to prime CD 8 T cells but APC could acquire antigen and dsRNA from transfected 
myoblast cells implicating cross-priming mechanism in the activation of CD8
+
 T cells [80]. 
To better elucidate the mechanism by which BM-DCs are able to take up endogenous expressed 
antigen from myoblast cells, BM-DCs were cultured in the upper compartment of a trans-well 
chamber in which infected C2C12 were transfected with VRP (NP) and placed 12 hours before 
in the lower compartment. After 2 hours, BM-DCs migrated in the lower compartment of the 
trans-well chamber. BM-DCs, which are not adherent cells, are easily separated from myoblast 
cells and collected. C2C12 were also collected and LC- SRM assay was applied to evaluate the 
NP antigen amount/distribution in the two cellular lines.  
Quantification of NP protein antigen was performed, evaluating the precise amount of NP in 
myoblast cells before and then adding BM-DCs. Moreover the amount of NP protein was 
measured also in BM-DCs. Results were summarized in the Figure 36.  
From the obtained results we can observed that the total amount of NP protein antigen in 
myoblast cells decrease from around 1.22 pmol in the first time point to around 0.6 pmol after 
two hours. This is concomitant with the new presence on BM-DCs of NP protein antigen with an 
amount of around 0.7 pmol in total cell lysate. 
 
Fig. 36. Absolute quantitation of NP antigen in 1 μg of C2C12 and BM-DCs cells in a co-culture 
experiment. 
The absolute quantification of NP antigen expressed in fmol/μg of total cell lysate was evaluated. In red 
the total amount of NP in C2C12 cell prior and then the adding of BM-DCs was measured. In blue the 
quantification on BM-DCs was perform after 2 hours of co-culture. 
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This concomitance and amount distribution are another demonstration that BM-DCs are able to 
take up endogenous protein antigens from myoblast cell and denying the possibility that during 
this short interval NP antigen is directly produced by BC-DCs from the dsRNA [80]. Moreover 
preliminary results showed a further increase of antigen presence in BM-DCs harvested after 5 
hours, higher than the original amount observed in myoblast cells. Possible explanation could be 
possibility of a direct antigen expression in BM-DCs from the dsRNA up taken from myoblast 
cells. Furthermore, immunoaffinity purification of MHC class I bound peptides from BM-DCs at 
2 hours post co-culture with myoblast cells was performed (as described in 3.3 in results section 
and 4.11 of material and methods section) to potentially detect and quantify immunodominant 
MHC class I peptide. No detection of MHC-I peptide was obtained even if the amount of NP 
antigen quantified in BM-DCs correlates with those in myoblast when antigen presentation 
occurs. New later time points (3-5 hours) could be useful to deepen this aspect and better 
understand the molecular mechanism of action of this new kind of vaccines.  
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CONCLUSION 
 
In the 21
st century, vaccines will play a major role in safeguarding the world’s health. However, 
despite advances, many medical needs remain and current new technologies are now able to 
bring innovations in the vaccine field. Nucleic acid based vaccines have long held the promise to 
address these needs but despite decades of research and development there is still no licensed 
vaccine for human use. Among them, RNA vaccines (mRNA or self-amplifying) has emerged 
during the last decades as good alternative to recombinant viral vector or DNA technology, with 
a number of high profile reports using RNA for vaccines and gene therapy application.  
However even if naked RNA (mRNA or self-amplifying RNA) induces in vivo protein 
expression and generate immune response, they suffer from limited potency in part due to in vivo 
RNA instability, related their intrinsic biochemical nature and to the presence of degradative 
enzymes in tissues. For these reasons, there has been extensive work on the delivery of self 
amplifying mRNA using no viral system. The SAM vaccine technology in which the delivery 
was facilitated by lipid nanoparticles, synthetic vehicles such as liposomes and cationic polymers 
that bind the RNA, enhances its delivery and increase potency of the vaccines. SAM vaccine has 
been widely evaluated in different animal model and has been confirmed to be well tolerated and 
able to drive, for the nature as replicon, high level of antigen expression, showing to elicit broad 
and potent humoral and cellular immune response against several pathogens comparable with 
those obtained by viral delivery (VRPs). 
However, little has been published on the mechanism of action of these vaccines. To date it is 
known that myocyte cells and not immune cells (antigen presenting cells) seem to be the 
predominant cell type transfected within the injection site at time of vaccination [24]. Moreover, 
recent studies demonstrate that in vivo priming of MHC class-I restricted CD8
+
 T cells following 
SAM immunization involves bone marrow-derived professional APCs. Therefore, myocytes can 
only provide an antigen source for the induction of a MHC class-I restricted CD8
+
 T cell 
response by APCs [80].  
In this scenario, the aim of this study was to provide a better understanding of the in vivo 
kinetics of antigen expression and its subsequent endogenous processing on MHC class I 
molecules, during SAM vaccination.  
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Previous studies were focus on the analysis of SAM vaccines encoded antigen expression and 
localization, in a in vivo model system based on reporter genes as firefly luciferase or secrete 
alkaline phosphatase (SEAP), where bioluminescence or chemoluminescence were the 
parameters monitored. With these assays a strong signal induced by LNP/RNA were observed, 
comparable to those produced by VRPs, that peaks early and persist for long time after SAM 
immunization. These kinds of assays don’t allow us to obtain precise quantitative information 
insight the kinetics of protein expression. To overcome all this limitation, a quantitative mass 
spectrometry (MS) approach was applied In fact rapid advances in MS instrumentation are 
enabling to perform relative and absolute quantification analysis. The method of choice in this 
field is the Selected Reaction Monitoring (SRM), a quantitative mass spectrometry approach that 
allows the precise and absolute quantitation of a specific set of proteins. Thanks to this, we 
focused our attention to the expression of antigenically conserved protein Nucleoprotein (NP) 
from Influenza virus. Furthermore, as intracellular encoded protein, NP could be used to build up 
a unique simple model system to monitor simultaneously intracellular antigen expression and the 
following endogenous processing and presentation on MHC class I molecules.  
Here, we started the study setting up an in vitro cellular model using the myoblast cell line 
C2C12. SRM have been applied to investigate the quantitative correlation between antigen 
expression and epitope presentation on MHC class I molecules in a time course experiment, 
using two different delivery systems for RNA, the Viral Replicon Particles (VRPs) and the 
synthetic Lipid Nanoparticle (LNPs for SAM)), also in order to better to understand the main 
differences that occur during SAM and VRPs immunization.  
RNA encoding NP protein was synthetized by in vitro transcription reaction and characterized 
for its self-amplification capability and expression of NP antigen in BHC cells and then 
formulated in VRPs and synthetic LNPs, in order to enhance RNA delivery and potency.  
From our results, a different temporal expression was observed between the two delivery 
systems. With VRPs antigen expression was observed at two hours post infection, differently to 
LNPs where antigen expression was detected at 12 hours post transfection. 
The early antigen detection and quantitation evaluated with VRPs are probably related to the 
high infection capability of alphavirus particle. Moreover the time frame required for protein 
detection observed in our experiment (2 hours) is consistent with previously published data that 
report how alphavirus infection process occurs. In fact when virus genome is transferred to host 
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cell cytoplasm, the detection of viral encoded proteins in infected cells occurs in a time frame of 
1-2 hours as observed in our experiment. On the other end, with LNPs, where the cellular-
liposome connection is mediated by electrostatic interaction between the cationic lipid and 
plasma membrane, we observed lower and later antigen expression. This is probably due to a 
slower LNPs internalization or RNA release in the cells or moreover to PEG-mediate liposome 
aggregation, which prevents desirable cell internalization.  
Then, to identify the kinetic correlation between NP protein antigen build-up and the subsequent 
endogenous processing on MHC class I peptide epitope, after both VRPs infection and LNPs 
transfection, SRM approach was applied to perform immunodominant epitope precise 
quantitation. A dynamic setting in which antigen levels are changing after transfection/infection 
can provide more insights into the relationship between antigen and epitope level. From our 
results is clear that, after NP-VRPs infection and NP-LNPs transfection, epitope presentation is 
essentially coincident with neo-synthesis of the source protein. Moreover, even if the source of 
protein continues slowly to rise, epitope turnover is rapid and not more detectable after this 
point. These results are consistent with previously published data [51], where the kinetic of 
multiple vaccinia virus peptides epitope and corresponding viral protein were monitored by 
SRM. In that work, immunodominant peptide epitope, displayed on surface of dendritic cells, 
was characterized by a similar behavior, providing the strong evidence that antigen presentation 
is temporally linked to translation and not with later degradation of the antigen. The epitope 
abundance measured in our experiment is ten times lower than the amount observed in the 
mentioned study. Actually, even if, muscle cells can acts as APC in the immune system, they do 
not express the CD80-CD86 costimulatory molecules, need for efficient presentation. Moreover, 
a high dynamic process characterized by multiple epitope simultaneously detected by SRM was 
described in the same study. In the same way, the analysis of MHC class I presentation of SAM 
vaccines through the immunodominant peptide, might not reflect the whole complexity and 
mechanism of presentation. Future works will focus to get more inside this dynamic process. To 
conclude this part, no evident differences in the intracellular NP expression and peptide epitope 
presentation was observed after protein detection between the two considered delivery systems. 
We can assume that the different behavior between VRPs and LNPs is only related to a different 
mechanism of cellular uptake and internalization. 
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To better elucidate the antigen expression step upon SAM vaccination, we moved toward an in 
vivo mouse model system where NP antigen was monitored at the site of injection in muscle and 
lymph node at 6 hours, 1 day, 3 day, 8 day and 10 days post immunization.  
The abundance of NP protein antigen was precisely quantified on the treated total muscle, for 
each time points, showing that with 0.1 μg of SAM-LNPs, 25 ng of NP protein antigen was 
detected at 6 hours and no increase was observed until 8 days post immunization where amount 
was measured around 56 ng. Despite the magnitude of elicited immune response between SAM 
and commercial subunit vaccines is comparable, with this data is clear that this new type of 
vaccine are able to generate at the side of injection an amount of antigen lower respect to the 
standard dose given by classical vaccines (20-50 µg). 
Then to delve deep into the SAM immune response, we focus on professional antigen presenting 
cells. Previously studies have been evidenced that DCs are not directly transfected by SAM, but 
are able to uptake endogenous antigen from transfected myoblast cells. To better elucidate this 
point, SRM approach was applied to describe antigen amount and its distribution between DCs 
and myoblast during co-culture experiment. The data obtained showed a decrease of protein 
amount in myoblast cell concomitant with the presence of antigen in DCs. This could be 
explained by the possibility that DCs acquired endogenous protein antigen from myoblast cell 
were expression take place.  
Moreover, studies are in place to identify the peptide repertoire presented on the surface of DCs. 
In summary we confirmed the pivotal role of muscle cells in antigen expression step during 
SAM vaccination in both in vitro and in vivo models, defining the kinetic of antigen expression 
and the subsequent endogenous processing on MHC class I. Further studies will be performed to 
better elucidate antigen presentation in DCs, improving, with new methods and technologies, the 
current knowledge about the mechanism of action of this new kind of vaccines.  
Moreover, this study also demonstrated the power of MS for the quantitation and identification 
of MHC-associated peptides for T-cell epitope discovery and its use to optimize and inform 
vaccine design [47].  
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MATERIAL AND METHODS  
 
4.1 RNA synthesis 
 
Influenza NP gene was amplified from the cDNA of the influenza virus A/Puerto 
Rico/8/34 (H1N1), and then were cloned as a SalI and NotI fragment into an optimized replicon 
construct [29, 85]. Briefly, DNA plasmids encoding NP (SAM(NP)) replicons were amplified in 
Escherichia coli and purified using Qiagen Plasmid Maxi kits (Qiagen). DNA was linearized 
after 3’ end of the self-amplifying RNA sequence by digestion with PmeI. Linearized DNA 
templates were transcribed into RNA using the MEGAscript T7 kit (Life Technologies) and 
purified by LiCl precipitation. RNA was then capped using the ScriptCap™ m7G Capping 
System (Cell Script) and further purified by LiCl precipitation.  
 
4.2 BHK cell transfection and NP expression evaluation 
 
Baby hamster kidney cells (BHK) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Carlsbad, CA) containing 5% (v/v) fetal bovine serum (FBS) (Hyclone) at 
37°C at 5% CO2 incubator, and transfected at 80% confluence. 
To determine the efficiency of RNA self-amplification, BHK cells were electroporated (120V, 
25ms pulse) with 200 ng of RNA and incubated for 16-18 h at 37°C in a CO2 incubator. Cells 
were collected, stained with Live/Dead Aqua (Invitrogen), fixed and permeabilized with 
Cytofix/Cytoperm (BD Biosciences), and stained with Allophycocyanin (APC)-conjugated anti-
dsRNA antibody (J2 monoclonal mAb mouse IgG2a kappa chain, Bioclass). Anti-dsRNA IgG2a 
was conjugated using the Zenon APC labeling kit (Invitrogen). Frequencies of dsRNA
+
 cells 
were measured by flow cytometry on a FACS Canto II flow cytometer (BD Biosciences). 
To determine the efficiency of protein expression, BHK cells were transiently transfected in a 6-
well plate with 3 µg of each SAM construct and LIPOFECTAMINE 2000
TM
 (Invitrogen) 
according to manufacturer’s instructions. BHK cells were collected 18-20 h after transfection 
and lysed using RIPA buffer (Sigma) supplemented with complete protease inhibitor cocktail 
(Roche), and whole cell lysates were separated under reducing conditions on a 4–12% Bis-Tris 
polyacrylamide gel in MES electrophoresis buffer (Life Technologies) and blotted onto PVDF 
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membranes (Life Technologies). NP was detected with anti-NP antibody (HB65 purified 
Hybridoma; ATCC Clone H16-R10-4R5) and reveled using a Goat anti-Mouse IgG HRP 
secondary antibody (Thermo Fisher). 
 
4.3 Production of viral replicon particles (VRPs) 
 
VRPs were produced in BHK cells as previously described [62]. In this system, the 
antigen expressing alphavirus chimeric replicon vector (VCR) derived from the genome of 
Venezuelan equine encephalitis virus (VEEV) engineered to contain the 3′ untranslated region 
(3′ UTR) and the packaging signal (PS) of Sindbis virus (SV), was electroporated into BHK cells 
along with defective helper RNAs encoding the Sindbis virus capsid and glycoprotein genes. 
 
4.4 LNP/RNA formulation  
 
RNAs were encapsulated in LNPs as previously described [29, 86]. 
Briefly, the lipids 1,2–dilinoleyloxy–3–dimethylaminopropane (DLinDMA) [87], 1,2–
Diastearoyl–sn–glycero–3–phosphocholine (DSPC, Genzyme), 1,2–di-myristoyl–sn–glycero–3–
phosphoethanolamine–N–[methoxy(polyethylene- glycol)–2000] (ammonium salt) (PEG–DMG 
2000; Avanti Polar Lipids) and cholesterol (Sigma–Aldrich) were dissolved in ethanol at a ratio 
of 40:10:2:48 (v/v/v/v). RNA in 100 mM citrate buffer pH 6.0 (Teknova), was combined with 
the lipid solution through a T-junction via a KDS-220 syringe pump (KD Scientific) considering 
a molar ratio of 8:1 between nitrogen (N) from DLinDMA and phosphate (P) from RNA. An 
additional buffer volume of 100 mM citrate buffer (pH 6.0) was added simultaneously to the 
RNA/lipid suspension to obtain the final RNA/lipid nanoparticles. The resulting LNPs were 
dialyzed overnight at 4°C against PBS pH 7.4 (Ambion) using Pierce slide-A-Lyzer
®
 G2 dialysis 
cassettes (Thermo Scientific) with a 3.5 K membrane molecular weight cut off. Formulations 
were characterized for particle size, RNA concentration, encapsulation efficiency and antigen 
expression in transfected cells. Prior to administration, LNPs were diluted in PBS to the desired 
concentration (1 ng/l). 
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4.5 Induction of Bone Marrow-Derived Dendritic Cells (BM-DCs) 
 
BM-DCs were induced from bone marrow (BM) cells obtained from 6-8 weeks-old C3H 
mice as previously described [88]. Briefly, a single cell suspension was prepared from BM 
obtained from femurs. After lysing red blood cells, 2x10
6
 BM cells were cultured in RPMI 1640 
medium (Gibco) supplemented with 25 mM HEPES (Gibco), 10% heat inactivated FBS (low 
endotoxin, HyClone), Penicillin/Strepmicyn/Glutamine (Pen/Strep/Glu) antibiotic solution 
(100x, Gibco), 50 μM β-mercaptoetanol (Sigma) 10 ng/ml mouse GM-CSF (Gentaur) and 5 
ng/ml mouse IL-4 (Miltenyi) in 10 cm diameter Petri dishes at 37 °C in 5% CO2. Supplemented 
medium was refreshed every three days. On day 8, non-adherent and DCs were collected and 
analyzed for CD11c expression by flow cytometry using APC-eFluor780-labeled anti-CD11c Ab 
(eBioscience). All prepared BM-DC population used expressed CD11c on at least 60 % of the 
cells. 
 
4.6 C2C12 infection  
 
C2C12 (H-2k MHC I aplotype) mouse myoblasts cells were obtained from ATCC 
(Rockville, MD) and maintained in high-glucose Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco) supplemented with 10% (v/v) FBS and  Pen/Strep/Glut (Gibco). C2C12 cells were 
infected using VRPs expressing NP. The day before infection, C2C12 cells were plated in a 24 
well plate in culture media without antibiotics. Culture media was then removed and 100 µl of 
DMEM containing only 1% FBS and 10
6
 VRPs (NP) infectious units (IU) were added to the 
cells. After incubation at 37°C for 1 hours, 400 µl of complete culture media was added to the 
cells for 2 4 12 and 24 hours incubation. Cells were then washed with PBS, trypsinized and 
further analyzed by flow cytometry for NP and H-2k expression using a FITC-labeled anti-NP 
(Thermo Fisher). Cells were further pelleted and keep at -80 °C for proteomic analysis.  
 
4.7 LNP/RNA in vitro transfection  
 
C2C12 and BM-DCs were transfected in a 24-well plate using serial dilutions of LNP 
formulated SAM (NP). The formulation stock was diluted until a final concentration of 10 
μg/mL in DMEM (Gibco) containing only 1 % (v/v) FBS (EuroClone) for C2C12 cells or RPMI 
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1640 medium (Gibco) supplemented with 25 mM HEPES (Gibco), 10 % (v/v) heat inactivated 
FBS (low endotoxin, HyClone), Pen/Strep/Glut (100x, Gibco) and 50 μM β-mercaptoetanol 
(Sigma) for BM-DCs.  
Diluted formulates were then pre-incubated in respectively working medium added with FBS 
(10% (v/v) final) at 37°C for 15 min and then incubated with cells at desired dilutions in 
respectively growth media (1% (v/v) FBS final) for 4-12-24 hours. 
The media was then removed, and cells were trypsinized and stained with the Live/Dead Fixable 
Yellow viability marker (Invitrogen). BM-DCs were stained also with APC-eFluor780-labeled 
anti-CD11c Ab (eBioscience). Cells were fixed and permeabilized with Cytofix/Cytoperm (BD 
Biosciences), washed with Perm-wash buffer (BD Biosciences) and stained with a FITC-labelled 
anti-NP antibody (Thermo Fisher) and anti-dsRNA antibody (Bioclass), previously conjugated 
with Zenon Allophycocyanin Labeling kit (Invitrogen). Stained cells were acquired on LSR II 
SOS1 flow cytometer (BD Biosciences) and analysed with FlowJo software (TreeStar). For BM-
DCs analysis, NP
+
 and dsRNA
+
 DCs were gated on CD11c
+
 cells. Cells were pelleted and keep 
at -80 °C for proteomic analysis.  
 
4.8 Filter Assisted Sample Preparation (FASP) method for LC-SRM 
of total cell lysate  
 
C2C12/BM-DCs cell pellet were lysed in 150 µl of solution containing 4% (v/v) sodium 
dodecylsulfate (SDS), 100 mM TrisHCl pH 7.6, 0.1 M dithiothreitol (DTT) and incubated 30 
min in ice . Obtained lysate was centrifuged at 16,000 x g for 10min and from the collected 
supernatant, total protein content was evaluated by colorimetric techniques as Bicinchoninic acid 
assay (BCA Assay Kit, Sigma Aldrich). These freshly prepared cell lysates contain 
contaminants, such as salt, detergents, nucleic acids, and lipids that can interfere with the 
subsequent analysis, for this, protein extract was subjected to FASP method for MS sample 
preparation.  
20 μg of protein extract was mixed with 400 µl of 8 M urea (Sigma) in 0.1 M Tris-HCl pH 8.5 
(UA) in filter unit (Microcon YM-30 Millipore) and incubated at RT for 30 min. Filter was then 
centrifuged at 14,000 x g for 15 min and washed twice with UA. Alkylation of cysteine residue 
of protein was performed adding to the filter 50 mM iodoacetamide in UA (IAA). The solution 
was mixed at 600 rpm in a thermo-mixer for 1 min and then incubates in the dark without mixing 
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for 20 min at 37 °C. After this time frame, filter was centrifuged again at 14,000 x g for 20 min 
and washed twice with UA. pH was then adjusted to 8 by washing filter twice with 50 mM 
ammonium bicarbonate (ABC). Isotopically labeled peptides (25 fmol for 1μg of total protein 
content), required for precise quantification by targeted LC-SRM were added at this stage, in 
order to account losses during sample preparation. Trypsin digestion was performed overnight 
incubating sample with 1 μg of trypsin (Gold MS Grade Promega) (25:1-sample: trypsin) at 37 
°C. 
Peptide mixtures were collected to centrifugation at 14,000 x g for 10 min and the digestion 
reaction was stopped with FA at 0.1% (v/v) final concentration, until obtaining acid pH (pH=2). 
The peptide mixtures were then desalted using OASIS cartridges (Waters), concentrated with a 
Centrivap Concentrator (Labconco, Kansas City, KS) and suspended in 20 μL of of 98% H2O, 
2% acetonitrile (CAN), 0.05% trifluoroacetic acid (TFA) (all v/v ratio). The SRM analysis was 
performed on a nanoUPLC Dionex (Thermo Fisher®) coupled with a triple-quadrupole mass 
spectrometer (TSQ Vantage, Thermo®) equipped with a nanoelectrospray ionization source 
(nano-ESI, Thermo Fisher). Samples were loaded fist in a trap column PepMap® 100 C18 
Columns  100 µm x 2 cm (Thermo Scientific®) at a flow rate of 5 µl/min performed by the 
loading pump (98% water, 2% acetonitrile and 0.05% trifluoroacetic acid). Peptides were 
separated using EASY-Spray column PepMap® RSLC C18 50 µm x 150 mm (Thermo 
Scientific®). A five-step 65 minute gradient with an injection volume of 2 μL was used. Buffer 
A contained 98% water, 2% acetonitrile and 0.1% formic acid; buffer B contained 98% 
acetonitrile, 2% water and 0.1% formic acid. PTP were measured by SRM assay in positive 
mode form 0 to 40 minutes. The following parameters were used: predicted collision energy 
values, Q1 peak width (FWHM): 0.70 Th, Q3 peak width (FWHM): 0.70 Th, Gas Pressure 
(mTorr): 1.2 bar, Tuned S-Lens value: Yes, cycle time (s): 1.000 DCV. Io order to optimize the 
collision energy three transitions per peptide was selected based on their relative intensity; 
transitions with the highest intensity were preferred. Then the corresponding collision energy 
was selected. 
 
4.9 Animal studies 
 
C3H mice, 5-weeks old, 4 mice/group were immunized by quadricep intramuscular 
injection (i.m.) on both hind legs with 25 μl of PBS containing 0,1 μg of SAM (NP/LNP) self-
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amplifying mRNA encoding NP antigen encapsulated in LNP. PBS alone was used as negative 
control. Mouse muscle and distal lymph node at the side of injection were collected at 6 hours, 1 
day, 3 days, 8 days and 10 days after immunization. Muscles and lymph nodes were immediately 
frozen in liquid nitrogen and stored at -80 °C.  
All animal studies were carried out in compliance with the arrive guidelines, the current Italian 
legislation on the care and use of animals in experimentation (Legislative Decree 116/92), and 
with the GSK Animal Welfare Policy and Standards. Protocols were approved by the Italian 
Ministry of Health (authorization 249/2011-B).  
 
4.10 Mouse tissue (muscle and lymph node) sample preparation for 
LC-SRM. 
 
Frozen mouse tissues were weighed, immediately disrupted in small pieces and lysated in 
a solution (1:10 w:v) containing 4% (v/v) SDS, 100 mM Tris-HCl pH 7.6, 0.1M DTT 
supplemented with complete protease inhibitor cocktail (Roche). 
Mechanical homogenation was performed in Fastprep
®
24 Homogenator (MP Biomedicals) 
through the multidirectional, simultaneous beating of specialized Lysing Matrix beads (Lysing 
matrix D -MP Biomedicals) formed by 1.4 mm ceramic spheres, put inside the sample. 
Homogenation of tissue suspension was done with 10 short bursts of 10 sec followed by intervals 
of 30 sec for cooling. Tissue lysate was centrifuged at 10,000 x g for 10 min and from the 
collected supernatant, total protein content was evaluated by BCA assay. These freshly prepared 
cell lysates contain contaminants, such as salt, detergents, nucleic acids, and lipids that can 
interfere with the subsequent MS analysis, for this, 2,2,2-trichloroacetic acid (TCA) precipitation 
method was used to isolate protein component.  
50 µg of total tissue lysate were denatured and reduced with 0.1 % (v/v) Rapigest
®
 (Waters) and 
5 mm DTT at 100 °C, for 10 min. Alkylation of cysteine residue was performed with 20 mM 
IAA incubating the solution in the dark without mixing for 20 min at 37 °C. 20 mM DTT was 
added to stop IAA reaction and after mixing, proteins were precipitated in ice for 2 hours adding 
10% (v/v) TCA and 0.1% (v/v) sodium deoxycholate (DOC). The mixed protein-detergent 
precipitate was collected by centrifugation (10,000 x g, 10 minutes 4°C). The supernatant was 
carefully removed, 400 μl of cold ethanol were added to wash the pellet and vortexing was 
carried out until the pellet was completely solubilized. Centrifugation was carried out as 
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described above. The supernatant was removed, pellet was further washed with 400 μl of cold 
ethanol. Finally, the pellet was dissolved in 50 μl of ABC (with 10 min. of sonication). 
Denaturation and reduction with 0.1% (v/v in H2O) Rapigest® (Waters) and 5 mm DTT at 100 
°C were performed again and after a cool down at room temperature, isotopically labeled 
peptides (25 fmol for 1μg of total protein content) and 2 µg of Trypsin (Gold MS Grade 
Promega
®
) were added. Digestion was carried out at 37 °C overnight and stopped with formic 
acid at 0.1% (v/v) final concentration until acidic pH (pH=2). The peptide mixtures were then 
desalted using OASIS cartridges (Waters) concentrated with a Centrivap Concentrator 
(Labconco, Kansas City, KS) and suspended in 20 μl of 0.1% (v/v) formic acid (FA). Samples 
were analyzed by SRM as described in 4.8 Material and method section. 
 
4.11 Purification of MHC class I peptide from treated cell line. 
 
MHC-bound peptide complexes are affinity purified from whole total cell lysate using Protein A 
Sepharose resin linked to MHC H2-K
K
monocolonal antibody.  
 
4.11.1 Preparation of Cross-Linked Immunoaffinity Column 
 
Protein A coupled with Sepharose resin slurry (2ml) was packaged into 1 ml column 
(Econo-Column® Chromatography Columns, 1.5 × 10 cm coupled with flow adaptor) and 
washed with 10 column volumes (c.v.) of MS-grade H2O and PBS respectively.  
Monoclonal antibody of MHC H2-K
K
 (4 mg 0.5 mg/ml in PBS) was added to column and leave 
to rotate gently end-over-end at 4 °C for 1 h to allow the binding. After this time frame antibody 
solution was allowed to flow throw by gravity and antibody-bound resin was washed with 20 c.v. 
of 0.05 M borate buffer pH= 8.0 followed by 15 c.v. of freshly prepared 0.2 M triethanolamine 
(Millipore), pH 8.2 at room temperature (RT). Triethanolamine was used to ensure that there are 
no residual primary amines present that may interfere with the cross-linking reaction. At this 
point, 5 c.v. of freshly prepared Dimethyl pimelimidate (DMP-2HCl, Sigma) cross-linker 
solution (40 mM DMP-2HCl in 0.2 M triethanolamine pH 8.3) was added through the column at 
RT leaving a meniscus just over the protein A column bed and allowed to sit at RT for 1 h. 
Cross-linking reaction was terminate the by adding 10 c.v. of ice cold termination buffer (0.2 M 
Tris-HCl, pH 8.0). 
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The unbound antibody was remove by washing with 10 c.v of stripping buffer (0.1 M citrate pH 
3.0) and 10 c.v. of PBS pH 7.4 was added to until pH of flow through was neutral. 
 
4.11.2 Generation of cell lysate-C2C12 treated with VRPs/LNPs 
 
C2C12 cells (5×10
8
) were grown in 24 well plates and treated with VRPs/LNPs as 
previously described. Cell were washed in PBS, and harvested by centrifugation (2,000 × g, 10 
min at 4 °C). Cell pellets (pellet derived from 5×10
7 
per 1 ml of lysis buffer) were lysated in 
Lysis buffer constituted by  0.5 % (v/v) IGEPAL 630 (Sigma), 50 mM Tris-HCl pH 8.0 (from 1 
M stock solution), 150 mM NaCl, and protease inhibitor cocktail (Roche). 
Homogenation of cell suspension was done with 10 short bursts of 5 sec followed by intervals of 
30 sec for cooling with amplitude 20% in an ultrasonic sonicator (Q-sonica) and rotated end-
over-end at 4 °C for 1 h.  
Lysate was then centrifuged for 10 min at 2000 × g at 4 °C and the obtained supernatant was 
spun for 75 min (100,000 × g) at 4 °C. After this step, often a lipid-containing layer is presented 
on the top of the tube. This layer was removed carefully and then the obtained lysate was filtered 
through a 0.8 μm and 0.45 μm filter.  
 
4.11.3 Immunoaffinity purification of MHC class I peptide 
 
Cell lysate was loaded onto a protein A Sepharose pre-column previously equilibrated in 
10 c.v. of wash buffer 1. Pre-cleared lysate was collected and slowly load onto the cross-linked 
mAb MHC H2-K
K
 (Thermo Scientific) with a constant flow of 1 ml/min.  
Column was washed with 20 c.v. of wash buffer in the following order: Wash buffer 1, wash 
buffer 2 (needed to remove detergent), wash buffer 3 (needed to remove no specifically bound 
material), wash buffer 4 (needed to remove salt to prevent crystal formation) and MHC 
complexes were eluted in 5 c.v. of elution buffer. Isotopically labeled peptides, required for 
precise quantification by targeted LC-SRM were added at this point. MHC bounded peptides 
were then separated from heavy chain, β2m and detergent by low protein binding spin filter. The 
obtained peptide mixtures were then desalted using OASIS cartridges (Waters), concentrated 
with a Centrivap Concentrator (Labconco, Kansas City, KS) and suspended in 20 μL of 98% 
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H2O, 2% CAN, 0.05% TFA. Samples were analyzed by SRM as previously described in 4.8 
Material and methods section. 
Solutions: 
 Wash buffer 1: 0,005% IGEPAL 630, 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA 
in MS grade H2O. 
 Wash buffer 2: 50 mM Tris-HCl, pH 8.0, 150 mM NaCl in MS-grade H2O. 
 Wash buffer 3: 50 mM Tris-HCl, pH 8.0, 450 mM NaCl, in MS-grade H2O. 
 Wash buffer 4: 50 mM Tris-HCl, pH 8.0 in MS-grade H2O. 
 Elution buffer: 10% (v/v) acetic acid in MS-grade H2O. 
 
4.12 SISCAPA enrichment for low abundance protein quantitation 
 
4.12.1 Rabbit immunization 
 
Immunogens consisted of the target tryptic peptides (NP-PTPs) and MHC class I 
immunodominant peptide, (synthesized and quantified JPT Peptide Technologies GmbH 
according to amino acid composition analysis) that had been conjugated to keyhole lympet 
hemocyanin (KLH) and Bovine ovalbumin (BSA) via an N-terminal cysteine and succinimidyl 
trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) (conjugation performed by JPT 
Peptide Technologies GmbH).  
New Zeeland White female rabbit, 9-weeks old, 2 rabbits/group were immunized using a 
standard protocol of three immunizations on days 1, 21 and 35 and 2 bleeds for each rabbit. The 
subcutaneous injections were performed using the BSA-immunogens as follow:  
 SALILR peptides conjugated to bovine serum albumin (BSA) 
 GVFELSDEK peptides conjugated to bovine serum albumin (BSA) 
 EGYSLVGIDPFR peptides conjugated to bovine serum albumin (BSA) 
 SDYEGRLI peptides conjugated to bovine serum albumin (BSA) 
All immunogens at the time of each injection was thawed and combined with 2 mg Alum 
Hydroxide (AlOH3) adjuvant in 100 mM Histidine buffer, 2M Sodium Chloride and water for 
injection to 500 μl final volume. Formulates were then characterized for the pH, osmolality, 
formation of visible precipitates and for Alum adsorption by SDS-PAGE. Serum bleeds of 7.5 ml 
for each rabbit were obtained after the third immunizations (15 ml total). For each peptide target 
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group, the rabbit with the higher titer, as measured by peptide ELISA, was chosen for antibody 
purification as described below.  
 
4.12.2 Antibody screening by peptide ELISA  
 
Sera from each rabbit were tested for ELISA activity against the corresponding peptides 
group (see above). The peptide ELISAs were performed as reported [89]. Briefly, Maxisorp 
plates were coated overnight at 4 °C with 2 μg/ml of each peptide conjugated to KLH in PBS. 
The wells were washed once using 100 μl of Tris Buffer Saline (500 mM Tris, 60 mM KCl, 2.8 
M NaCl ) TBS plus 0.1% (v/v)Tween 20 (TBST) and blocked using 60 μl of TBST-0,1 % BSA 
(v/v) for 1 hour at RT. Serum samples and a standard serum were 2-fold serially diluted in PBS 
with 1% BSA and 0.05% (v/v) Tween-20, and transferred into coated and blocked plates. After 2 
h at 37 °C, plates were incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG 
(Sigma) for 90 min at 37°C to detect antigen-specific IgG antibodies. The plate was washed three 
times with 100 μl TBST and 50 μl of p-nitrophenyl phosphate, disodium salt (PNPP, Pierce) was 
added. Color was allowed to develop for 15 minutes at RT. Fifty microliters of 3 M NaOH was 
used to stop the reaction, and OD was measured at 405 nm.  
 
4.12.3 Purification of Abs from rabbit serum 
 
Purification of IgG was performed using Hi Trap Protein G HP columns 5 ml column 
(GE Healthcare Life Sciences) connected to AKTA purified. The column was first washed with 
5 c.v. of distilled water and then equilibrate with 5 volume of binding buffer (300 mM NaCl, 50 
mM sodium phosphate, pH 8.0) with a flow rate of 5 ml/min. Than 20 ml of higher ELISA titer 
sera for each target group were loaded. 10 c.v. of binding buffer were loaded at flow rate of 1 
ml/min. The elution was performed using a one-step linear gradient with 10 c.v. of elution buffer 
(0.2 M glycine-HCl, pH 2.6). Immediately after the pH was neutralized using the neutralizing 
buffer (1 M Tris-HCl, pH 8).  
To assess the integrity of the IgG purified a SDS-PAGE was performed. The purified fraction 
were dialyzed against dialysis buffer (PBS), using 10 kDa molecular weight cut-off (10K 
MWCO) "Slide-A-Lyzer" cassettes (Thermo Fisher
®
). Dialysis was carried out for 2 hours at 
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room temperature, then the dialysis buffer was changed and dialysis was allowed overnight. 
Dialyzed samples were again analyzed by SDS-PAGE and quantified by BCA assay.  
 
4.13 In solution digestion and nano LC-MS/MS analysis 
 
Samples contained commercially available form Influenza A H1N1 Nucleoprotein /NP 
protein (His tag) (Sino Biological Inc.) were denatured and reduced with Rapigest® (Waters) 
and 5 mm DTT at 100 °C, respectively, for 10 min. After a cool down at room temperature, 50 
mM ammonium bicarbonate and 2 µg of Trypsin (Gold Mass Spectrometry Grade Promega
®
) 
were added. Digestion was carried out at 37 °C overnight. The digestion was stopped adding FA 
at 0.1% (v/v) final concentration until acid pH (pH=2).  
The peptide mixtures were then desalted using OASIS cartridges (Waters) following the 
manufacturer's protocol. Desalted peptides were concentrated with a Centrivap Concentrator 
(Labconco, Kansas City, KS) and suspended in 50 μl of 0.1% (v/v) FA.  
Peptides solution were analyzed by LC-MS/MS performed on a nanoAcquity UPLC system 
(Waters
®
) coupled a Waters SynaptG2 ESI mass spectrometer equipped with a nanospray source 
(Waters
®
). Samples were loaded onto a trap Symmetry C18 180 µm x 20 mm, 5µm (Waters
®
) 
using a full loop injection at a flow rate of 800 nl/min in a mobile phase A (0.1% FA). Peptide 
were than separated on a nano Acquity UPLC Peptide BEH C18 Column  75 µm x 100 mm 
(Waters
®
) using a 70 min gradient 3-98% mobile phase B (98% (v/v) ACN, 0.1% (v/v) FA) at a 
flow rate of 300 nl/min. 
The eluted peptides were subjected to an automated data-dependent acquisition (DDA) using the 
MassLynx software (Waters
®
) where an MS survey scan was used to automatically select multi 
charged peptides over the m/z ratio range of 300–2,000 for further MS/MS fragmentation. Up to 
eight different peptides were individually subjected to MS/MS fragmentation following each MS 
survey scan. After data acquisition, individual MS/MS spectra were combined, smoothed, and 
centroided using ProteinLynx, (Waters
®
) to obtain the peak list file (pkl). Protein identification 
was carried from the generated peak list using the Mascot engine software (Matrix Science). 
Peptide identification was run on a database containing all Influenza virus protein sequences 
deduced from the sequenced Influenza virus H1N1 genomes, downloaded from NCBInr 
database. Search parameters as variable modifications were : methionine oxidation, glutamine 
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and asparagine deamidation, trypsin cleavage (cleaves the C-term side of KR unless next residue 
is P), peptide mass tolerance as 0.15 Da, peptide MS/MS tolerance as 0.15 Da, missed cleavage= 
2, ion charge states: +2, +3, +4). Only significant hits were considered as defined by the Mascot 
scoring and probability system >25. 
 
4.14 Selection of proteotypic peptide and in Solution Tryptic 
Digestion 
 
In solution tryptic digestion and LC-MS/MS analysis were used to identify specific 
proteotypic peptides required for NP protein quantitation. 
From this obtained Mascot list, NP specific peptides that not displayed amino acids with 
chemical modifications occurs during sample preparation (glutamine and asparagine 
deamidation, cysteine and methionine oxidation, N-terminal glutamic acid for cyclization), and 
present a specific length from 5 to 20 amino acids were selected. Moreover peptides with low 
MS intensity signal (low Mascot score) and characterized by KK, RK, RR, KR consecutive 
amino acids, cause of an incomplete tryptic digestion, were not selected. Furthermore each PTPs 
were investigated for the unique association to the targeted protein in the specific biological 
background. For this reason the sequence of the selected PTPs were inspected against a database 
containing sequences deduced from the C3H mouse model genome and no matches were found. 
 
4.15 PTP dose-range linearity responses curve 
 
The dose-range linearity response of all PTPs in a specific matrix was assessed. Each 
point of this curve was measured with a fixed amount of matrix (1 μg of C2C12 total cell lysate 
or 1 μg of total tissue lysate-immuno-affinity purified peptides) and heavy form of PTPs (13C-
15
N-labeled Arg, Lys or Ile) and scalar concentration of light PTPs (ranging from 0.2 to 810 
fmol/µl or 0.2 to 51 fmol/μl in the case of MHC-I peptide). The protein mixture was digested 
with trypsin and the peptides were analyzed by LC-SRM as described in 4.8 Material and 
methods section. For each PTP, concentration was plotted against the peak area ratio obtained 
(light peak area/heavy peak area). From the dose-rang linearity curve the Lower Limit of 
Quantitation (LLOQ) for PTPs was identified and was set as the lowest concentration point on 
the fitted curve with an accuracy deviation ≤ 20%.  
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4.16 SRM analysis for the quantification of target protein/peptide in  
 a complex biological background 
 
All Peptides were analyzed by SRM assay in positive mode and the SRM method is 
reported below (RT means retention time in minutes).  
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